JC545 U.S. PTO
03/08/00

PATENT
Attorney Docket No. 1147-0142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OIPE JC65
MAR 0 8 2000
PATENT & TRADEMARK OFFICE

JC564 U.S. PTO
09/533906
03/08/00

In re Reissue Application of:
U.S. Patent No. 5,750,338

Mark L. Collins et al.

Group Art Unit: Unassigned

Reissue Serial No.: Unassigned

Examiner: Unassigned

Reissue Application Filed: Herewith

For: TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS

BOX REISSUE
Assistant Commissioner for Patents
Washington, D.C. 20231

REISSUE PATENT APPLICATION TRANSMITTAL

APPLICATION FOR REISSUE OF: ☒ Utility Patent ☐ Design Patent

1. ☒ Fee Transmittal Form
2. ☒ Specification and Claims (amended, if appropriate)
3. ☐ Drawing(s) (proposed amendments, if appropriate)
4. ☒ Reissue Oath/Declaration (original copy) (37 C.F.R. § 1.175)

LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

MAR 14 2000
TECH CENTER 1600/290

5. Original U.S. Patent

☒ Consent of Assignee, Offer to Surrender Original Patent, and Statement Under 37 C.F.R. § 3.73(b)

or

☐ Ribboned Original Patent

☐ Affidavit/Declaration of Loss

6. Original U.S. Patent currently assigned?

☒ Yes ☐ No

(If Yes, check applicable box(es))

☒ Written Consent of all Assignees

☒ 37 C.F.R. § 3.73(b) Statement

☒ Power of Attorney in U.S. Patent No. 5,750,338

7. ☐ Foreign Priority Claim (35 U.S.C. 119)

8. ☒ Information Disclosure Statement (IDS)/PTO 1449

☒ Copies of IDS Citations

9. ☐ English Translation of Reissue Oath/Declaration

10. ☐ Small Entity Statement(s)

☐ Statement filed in prior application, status still proper and desired

11. ☒ Preliminary Amendment

12. ☒ Also enclosed is: Associate Power of Attorney

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

MAR 14 2000
TECH CENTER 1600/2900

PATENT
Attorney Docket No. 1147-0142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of:
U.S. Patent No. 5,750,338

Mark L. Collins et al.

Reissue Serial No.: Unassigned

Reissue Application Filed: Herewith

For: TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS

Group Art Unit: Unassigned

Examiner: Unassigned

REISSUE APPLICATION FEE TRANSMITTAL FORM

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Claims as Filed - Part 1

Claims in Patent	For	Number Filed In Reissue Application	(3) Number Extra	Small Entity Rate	Small Entity Fee		Other Than a Small Entity Rate	Other Than a Small Entity Fee
(A)	Total Claims (37 CFR 1.16(j))	(B) 40	20 =	x$___=		or	x$18.00 =	$ 360.00
(C)	Independent Claims (37 CFR 1.16(i))	(D) 9	6 =	x$___=			x$ 78 00 =	$ 468.00
			Basic Fee (37 CFR 1.16(h))		$___	OR		$ 690.00
			Total Filing Fee		$___			$1,518.00

03/09/2000 MMARMOL 00000095 060916 5750338
01 FC:108 690.00 CH
02 FC:109 468.00 CH
03 FC:110 360.00 CH
04 FC:110 342.00 CH

Claims as Amended - Part 2

	Claims Remaining After Amendment		(2) Highest Number Previously Paid For	(3) Extra Claims Present	Small Entity Rate	Small Entity Fee		Other Than a Small Entity Rate	Other Than a Small Entity Fee
Total Claims (37 CFR 1.16(j))	59	MINUS	40	* = 19	x$_____=		or	x$ 18.00=	$ 342.00
Independent Claims (37 CFR 1.16(i))	9	MINUS	9	= 0	x$_____=			x$ 0 00 =	$ 0.00
				Total Additional Fee		$		OR	$342.00

Adjustment date: 06/08/2000 NVILLARI 00000095 060916 5750338
03/09/2000 MMARMOL
01 FC:108 690.00 CR
02 FC:109 468.00 CR
03 FC:110 360.00 CR
04 FC:110 342.00 CR

FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

If there are any fees due in connection with the filing of this Preliminary Amendment not already accounted for, please charge the fees to our Deposit Account No. 06-0916.

Respectfully submitted,
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: Jean Burke Fordis
Jean Burke Fordis
Reg. No. 32,984

Dated: March 8, 2000

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

Please charge the above-mentioned fees to our Deposit Account No. 06-0916. Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: Jean Burke Fordis
Jean Burke Fordis
Reg. No. Reg. No. 32,984

Dated: March 8, 2000

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

PATENT
Attorney Docket No. 1147-0142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of: U.S. Patent No. 5,750,338	)	
Mark L. Collins et al.	)	Group Art Unit: Unassigned
Reissue Serial No.: Unassigned	)	Examiner: Unassigned
Reissue Application Filed: Herewith	)	
For: TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS	)	

BOX REISSUE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

CONSENT OF ASSIGNEE, OFFER TO SURRENDER
ORIGINAL PATENT, AND STATEMENT UNDER 37 C.F.R. § 3.73(b)

Vysis, Inc. is the Assignee of the entire right, title, and interest in U.S. Patent No. 5,750,338 by virtue of an assignment from the inventors to Amoco Corporation in a predecessor application (U.S. Serial No. 07/136,920), recorded at Reel 4843, Frame 0373, and by virtue of a subsequent Assignment of Patents and Applications from Amoco Corporation to Vysis Inc (copy attached).

Vysis, Inc. hereby consents to the accompanying application for reissue of U.S. Patent 5,750,338.

Vysis, Inc. hereby offers to surrender U.S. Patent 5,750,338 when the reissue application is otherwise in condition for allowance.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

I am empowered to sign this paper on behalf of the Assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

March 8, 2000
Date

Norval B. Galloway, Reg. No. 33,595
Patent Counsel
Vysis, Inc.
3100 Woodcreek Drive
Downers Grove, Illinois 60515

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

PATENT

Attorney Docket No. 1147-0142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of: U.S. Patent No. 5,750,338	
Mark L. Collins et al.	Group Art Unit: Unassigned
Reissue Serial No.: Unassigned	Examiner: Unassigned
Reissue Application Filed: Herewith	
For: TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS	

BOX REISSUE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

This amendment is being submitted concurrently with a request for reissue of the above patent. Prior to reissue examination of this patent, please amend the application as follows.

IN THE CLAIMS:

Please amend claim 19, as follows:

19. A method for detecting a target polynucleotide contained in a sample, comprising the steps of:

(a) contacting the sample with a first support which binds to the target polynucleotide;

LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

(b) substantially separating the first support and bound target polynucleotide from the sample;

(c) amplifying the [sample] target polynucleotide with a DNA polymerase;

(d) contacting the amplified target polynucleotide with a second support which binds to the amplified target polynucleotide and also with a labeled probe which binds to the amplified target polynucleotide; and

(e) detecting the presence of the amplified target polynucleotide.

To the 40 claims that issued in the '338 patent, please add new claims 41-59 as follows:

41. The method for amplifying a target polynucleotide of claim 1 wherein the target polynucleotide is amplified *in vitro* to produce a multitude of polynucleotide amplification products.

42. The amplification method of claim 41 wherein the amplification is linear or exponential.

43. The amplification method of claim 42 wherein the amplification is exponential.

44. The amplification method of claim 41 wherein the target polynucleotide is amplified with a polymerase and at least one oligonucleotide primer.

45. The amplification method of claim 44 wherein the amplification is linear or exponential.

46. The amplification method of claim 41 wherein the target polynucleotide is amplified with more than one polymerase.

LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

47. The method for detecting a target polynucleotide of claim 7 wherein the target polynucleotide is amplified *in vitro* to produce a multitude of polynucleotide amplification products.

48. The detection method of claim 47 wherein the amplification is linear or exponential.

49. The detection method of claim 48 wherein the amplification is exponential.

50. The detection method of claim 47 wherein the target polynucleotide is amplified with a polymerase and at least one oligonucleotide primer.

51. The detection method of claim 50 wherein the amplification is linear or exponential.

52. The detection method of claim 47 wherein the target polynucleotide is amplified with more than one polymerase.

53. The method for detecting a target polynucleotide of claim 19 wherein the target polynucleotide is amplified *in vitro* to produce a multitude of polynucleotide amplification products.

54. The detection kit of claim 20 wherein the means for amplifying provide for *in vitro* amplification of the target polynucleotide to produce a multitude of polynucleotide amplification products.

55. The amplification kit of claim 24 wherein the means for amplifying provide for *in vitro* amplification of the target polynucleotide to produce a multitude of polynucleotide amplification products.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

56. The method for amplifying a target polynucleotide of claim 27 wherein the target polynucleotide is amplified *in vitro* to produce a multitude of polynucleotide amplification products.

57. The method for detecting a target polynucleotide of claim 28 wherein the target polynucleotide is amplified *in vitro* to produce a multitude of polynucleotide amplification products.

58. The method for amplifying a target polynucleotide of claim 34 wherein the target polynucleotide is amplified *in vitro* to produce a multitude of polynucleotide amplification products.

59. The method for detecting a target polynucleotide of claim 38 wherein the target polynucleotide is amplified *in vitro* to produce a multitude of polynucleotide amplification products.

REMARKS

In this amendment, the Patent Owner has amended original claim 19 to correct an obvious typographical error. Specifically, original claim 19 recited in step (c) the amplification of the "sample" with DNA polymerase but it should have recited amplification of the "target polynucleotide," as demonstrated by the recitation in steps (d) and (e) of further manipulations of the "amplified target polynucleotide." Thus, the Patent Owner requests entry of this amendment.

In addition, the Patent Owner has added new claims 41-59 (the specifics and support for which are discussed in detail below in the section entitled "Claims of Intermediate Scope") because, as set forth in the accompanying Reissue Declaration, the Patent Owner has recognized

LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

that the '338 patent is at least partially inoperative. Specifically, the Patent Owner believes that the inventors claimed, without any deceptive intent, less than they had the right to claim because the '338 patent does not contain claims of intermediate scope. These new intermediate scope claims provide additional protection for several narrower aspects of the invention. Thus, the Patent Owner seeks to add new claims 41-59 to obtain that protection.

Finally, a licensee of the '338 patent has suggested that the claims of the '338 patent might be read so broadly as to encompass prior art from an earlier period of molecular biology. The recitation in these new claims of three specific narrower aspects of the invention demonstrates more clearly that the claimed invention does not encompass this early art and, in any event, explicitly and even more clearly excludes the cited art. *See* Hewlett-Packard Co. v. Bausch & Lomb, Inc., 882 F.2d 1556, 1564-1565, 11 U.S.P.Q.2d 1750, 1757 (Fed. Cir. 1989) (expressing tacit approval of filing narrower claims in reissue, citing *In re Handel* 312 F.2d 943, 945- 46 n.2, 136 U.S.P.Q. 460, 462 n.2 (C.C.P.A. 1963)).

Thus, the Patent Owner respectfully requests entry of these amendments. With the requested amendments, claims 1-59 will be pending.

A. The Invention

As set forth during prosecution, the invention of the '338 patent provides polynucleotide assays that combine "target purification methods with target amplification methods." Paper No. 8, Preliminary Amendment of Dec. 5, 1995, at p. 11-12; Paper No. 12, Amendment of Oct. 24, 1996, at p. 10. Based on this combination, the invention provides methods of amplification that produce large amounts of purified target polynucleotide as well as methods of detection that

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

Serial No. 08/485,086

yield assays of great sensitivity. *Id.* Thus, the '338 patent issued with claims to methods of amplifying a target polynucleotide, methods of detecting a target polynucleotide, as well as kits for both amplifying and detecting.

Each of the claims, whether to amplification methods, detection methods, or kits, shares the sequential elements of purifying or separating the target polynucleotide from the sample and then amplifying the target polynucleotide. This particular combination of steps would not have been apparent or desirable to those in the nucleic acid assay art in December 1987, as set forth by the declaration of Dr. David Persing submitted during the prosecution of the '338 case.[1] Viewing it from the standpoint of amplification, those in the art believed that PCR (one of the primary methods of nucleic acid amplification) was so highly specific, based as it was on the careful selection of primers, that there was no need to isolate or separate target polynucleotides. Paper No. 20, Persing Declaration, ¶ 12. And, according to Dr. Persing, it was not until after December 1987 that those in the art recognized that careful selection of primers was not enough to avoid non-specific amplification. *Id.*

Second, from the binding/separating standpoint, it was generally understood that binding of the target to a probe/support was "substantially less than 100%." Thus, for assays in which the level of target polynucleotide was low, the use of a binding/separating step would decrease the already low amount of target available for detecting. Added to these concerns was the general

---

[1] A draft declaration was submitted on July 11, 1997 (Paper No. 20), and notice of the submission of the executed version was filed on July 11, 1997 (Paper No. 21).

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

05598.0006.00000

desire to avoid the addition of complex steps to the assay. Paper No. 20, Persing Declaration, ¶ 13. Accordingly, Dr. Persing concluded that:

> [C]oupled with the conventional understanding at that time (that careful selection of primers would permit adequate selectivity of target and specificity in the amplification product), the practitioners' concern regarding imperfect binding efficiencies and the expected loss of real target before amplification occurred reinforced their incentive to avoid further complicating their assays by the addition of target separation steps to their assays.

Paper No. 20, Persing Declaration, ¶ 13.[2]

The Examiner agreed in the Notice of Allowance, stating that:

> [T]he art at the time of filing did not recognize that the efficiency of PCR amplification would decrease due to the presence of contaminants in a sample and therefore provided no motivation to purify a target sample from a heterogenous sample of nucleic acids prior to amplification. Having not recognized the problem, applicant's solution therefore, while utilizing routine methodology to modify PCR amplification techniques, would not have been obvious at the time that the invention was made. The Declaration of Dr. David Pershing [sic] further supports this conclusion as providing further evidence concerning the skill of the art at the time of filing, attesting that one of skill in the art would likely stay away from combining a hybridization capture method with a PCR method since one would not be motivated to provide a method with the potential to lose target nucleic acids prior to amplification.

---

[2] Dr. Persing also noted an advantage of the claimed method that was unexpected in or before December 1987. Specifically, separating the target prior to amplification eliminates the effect of amplification inhibitors that are normally present in the sample system, thereby permitting amplification to proceed optimally. Paper No. 20, Persing Declaration, ¶ 14.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

Paper No. 23, Notice of Allowability, p. 3.[3]

Thus, claims 1-40 issued. As noted above, the claims recite methods of amplification (independent claims 1, 27, and 34), methods of detection (independent claims 7, 19, 28, and 38), and kits (independent claims 20 and 24). The claims provide for a variety of methods for separating the target polynucleotide, the simplest being providing a support to which the target polynucleotide binds and then removing the support from the sample (claims 1 and 7). Alternatively, the claims specify separation of the target by providing a probe which binds to the target and then providing a support which binds to the probe (claims 27 and 28) or by providing a support and a probe which binds to the target and to the support (claim 34 and 38). Similarly, the claims provide for a variety of methods for amplifying the separated target polynucleotide. The target polynucleotide can be amplified with any polymerase (claims 4, 10, 17, 25, 29, 35 and 39) or with a DNA polymerase, an RNA polymerase, a transcriptase, or Qβ replicase (claims 5, 11, 30, and 36).

[3] The Notice of Allowability speaks in reference to PCR in explaining the reasons for allowance. The inclusion of dependent claims that involve enzymes that were not and are not used in PCR (pending dependent claims 29 and 35 (which issued as claims 5 and 11, respectively) recite RNA polymerase and Qβ replicase) demonstrates, however, that the claims were never limited just to PCR, although they clearly were *in vitro* methods and were intended to be limited to making many copies of the target nucleic acid molecules as in PCR.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

05525906 - 030800

B. Claims of Intermediate Scope

Despite these specifically claimed elements of the amplification process, the specification discloses other aspects of the amplification method that had not been claimed. Accordingly, the Patent Owner seeks in this reissue application to add these aspects of the amplification process as claims of intermediate scope to provide additional protection to the claimed invention.

Specifically, the Patent Owner has added claims 41, 47, and 53-59 (which depend directly from each of the originally issued independent method of amplification claims 1, 27, and 34, from the method of detection claims 7, 19, 28 and 38, and from the kit claims 20 and 24)[4] that narrow the amplification method in three specific aspects. First, these new claims recite that the

---

[4] To orient the Office, the Patent Owner provides the following chart of the added claims and their relationship to the issued claims:

Type of claim	Original claim	Added claims
Method of amplification	1	41-46
	27	56
	34	58
Method of detection	7	47-52
	19	53
	28	57
	38	59
Kits	20	54
	24	55

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

Serial No. 90/006,601

amplification process is conducted *in vitro*. Each of the amplification examples set forth in the specification describes an *in vitro* method, as follows:

> - Example 4 describes amplification via *E. coli* RNA polymerase that lacks the sigma subunit (i.e., core RNA polymerase) together with nucleotide triphosphates and a low salt transcription buffer. See col. 30, line 59 to col. 31, line 19.
>
> - Example 5 sets forth a two stage process of amplification, first using DNA polymerase, random oligohexamer primers, and deoxynucleotide triphosphates in buffer to replicate the DNA and to produce additional double stranded DNA, followed by the addition of core RNA polymerase, nucleotide triphosphates and a low salt transcription buffer to form many RNA copies of the DNA. See col. 31, lines 28-54.
>
> - Example 6 amplifies first by non-specific double stranded DNA synthesis, as set forth in the first part of Example 5, followed by cycles of heating to form single stranded DNA and then polymerizing with additional DNA polymerase to yield an approximately 1,000 fold increase in the level of DNA. See col. 31, line 60 to col. 32, line 5.
>
> - Example 7 describes the exponential replication of RNA with Qβ replicase. See col. 32, lines 10-19.

Thus, these Examples support *in vitro* amplification methods.

Second, the intermediate claims all recite the production of a "multitude of amplification products." Express literal support is set forth in the specification, which states that:

> In Step 3 of FIGS 4, 5, and 6, the isolated target is non-specifically amplified to form a **multitude of amplification products**.

See col. 15, lines 56-58. In addition, because each of Figures 4, 5, and 6 corresponds to Examples 4, 5, and 6, respectively, these examples and figures support this limitation. Finally,

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

Example 7 supports the formation of a multitude of amplification products by its recitation of "exponential" replication of RNA.

Third, the intermediate claims also specify that the amplification products produced are "polynucleotide amplification products." That limitation finds support in the definition of "amplification" which recites enzymes that can only produce polynucleotide amplification products from polynucleotide targets, as follows:

> In the situation where the target is a polynucleotide, additional target, or target-like molecules, or molecules subject to detecting can be made enzymatically with DNA or RNA polymerases or transcriptases.

See col. 2, lines 16-19. In addition, all of the amplification examples (Examples 4-7) result in the production of polynucleotide amplification products, i.e., either RNA or DNA.

In addition to these intermediate claims, the Patent Owner has included additional dependent claims to the claims that ultimately depend from claims 1 and 7 to specify additional aspects of the amplification method. Specifically, claims 42, 45, 48, and 51 claim amplification wherein the amplification is linear or exponential. Examples 4 and 5, with their one-at-a time transcription of RNA and/or replication of DNA, are linear, while Examples 6 and 7, with the doubling of DNA per cycle, provide for exponential amplification. Indeed, Example 7 expressly notes the exponential nature of the process at col. 32, lines 17-19. Further dependent claims 43 and 49 specify an exponential amplification process.

The Patent Owner has also added dependent claims 44 and 50 to recite the use of a polymerase and at least one oligonucleotide primer because the specification covers

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

amplification both with and without primers. The support for claims with primers is expressly set forth in Examples 5-6, while the support for amplification without primers is set forth in Example 4.

Finally, the specification describes amplification methods based on more than one polymerase (see Example 5), and claims 46 and 52 cover those embodiments.

C. The Cited Art

As noted above, the lack of these intermediate claims has apparently resulted in some confusion regarding the scope of protection afforded by the patent because a licensee of the '338 patent has identified art that the licensee believes renders the claims unpatentable.[5] That licensee has suggested that the term "amplify" is used so broadly in the specification that the amplification method[6] includes the cloning of polynucleotides by growth in transformed cells; the production of cell-free translation products; and the enzymatic reproduction of a

---

[5] See redacted letter from licensee, attached at Tab 1.

[6] Although the licensee did not identify the particular claims to which these references applied, the licensee's characterization of the art demonstrates that the only claims to which the references could apply are the method of amplification claim 1 and the method of detection claim 7 and arguably to claims 34 and 38. Specifically, the licensee has urged that the references provide the binding of polynucleotides to solid supports, separating the support and the bound polynucleotide from the sample, and subsequently amplifying the polynucleotide. As noted above, both of these claims 1 and 7 recite the simplest capture method: contacting the sample with a first support, separating the support and bound target from the sample. Other independent claims recite additional elements. Specifically, the method of detecting claim 19 recites the step of separating out amplified target with a second support prior to detecting. The method of amplification claim 27 and the corresponding method of detection claim 28 further recite providing a probe which binds the target polynucleotide. Moreover, the references provide no suggestion for kits for amplification or detection as in claims 20 or 24.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

polynucleotide. The publications cited by the licensee and another publication that appears to be of the same ilk are submitted in an accompanying Information Disclosure Statement.

This apparent confusion over the protection afforded by the patent does not arise with respect to the intermediate scope claims set forth in this Preliminary Amendment. As noted above, these intermediate scope claims define the amplification element of each of the independent method claims in three separate aspects and thereby more clearly define the amplification method of the invention.

As to the specific differences between the claimed invention and the references set forth in the accompanying IDS, three of the references describe DNA cloning by insertion into a cloning vector and transformation of bacteria. Specifically, Arsenyan et al. *Gene* (1980) describes the insertion of double-stranded DNA, made by annealing purified single-stranded DNA fragments, into pBR325 and the transformation of *E. coli* (see page 101 or 106) and Georgiev et al. *Science* (1977) discusses the substitution of the DNA fragment of interest for the C fragment of the bacteriophage, λgt-λC, and the transfection of *E. coli* (see page 394). Neither of these *in vivo* DNA cloning papers from the earlier period of molecular biology describe the *in vitro* amplification of the claimed methods.

The third reference, Augenlicht, U.S. Patent No. 4,981,783, sets forth the insertion of DNA fragments into pBR322 and the transformation of *E. coli* (col. 5, lines 50-65). The patent also discloses that the number of plasmids per transformed cell is "amplified" by growth in the presence of chloramphenicol. As above, this disclosure of *in vivo* DNA cloning and increasing

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

plasmid number has nothing to do with the *in vitro* amplification method of the claimed invention.

Two of the references describe the enzymatic "reproduction" of a particular polynucleotide. Both of these references, Montgomery et al. *P.N.A.S.* (1982) and Boss et al. *P.N.A.S.* (1981), disclose the dideoxynucleotide chain termination technique of Sanger et al. using reverse transcriptase which is, in fact, a sequencing technique. The reverse transcriptase does produce a polynucleotide fragment (i.e., DNA) based on the target sequence but that fragment is not likely to be a copy of the target because the purpose of the sequencing method is to create fragments of different lengths, each ending with a labeled and chain-terminating nucleotide.[7] Moreover, reverse transcriptase can produce only one copy (whether it be a short or long fragment) of the target because it destroys the RNA target as DNA synthesis progresses.[8] Thus, neither of these disclosures sets forth a method that produces a "multitude" of amplification products.

The remaining two references describe cell-free translation methods which produce proteins. Specifically, both Hirsch et al. *P.N.A.S.* (1978) and Strair et al. *P.N.A.S.* (1977) used the "wheat germ cell-free system" to produce protein encoded by the isolated RNA. *See* Hirsch

---

[7] *See* Coulsen, A.R., and Staden, R., (1994) "DNA Sequencing" in *The Encyclopedia of Molecular Biology* (Edited by J. Kendrew, E. Lawrence et al., Blackwell Science Ltd, Oxford) pp. 283, 283-284 (copy enclosed).

[8] *See* Coffin, J.M. (1996), "Retroviridae: Viruses and Their Replication" in *Fundamental Virology,* Third Edition (B.N. Field, D.M. Knipe, P.M. Howley et al., eds, Lippincott-Raven Publishers, Philadelphia), pp. 763, 776-778 (copy enclosed).

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

at page 1736, right column, third paragraph; Strair at page 4348, right column, third paragraph. This production of protein is clearly outside the production of "polynucleotide amplification products" and, consequently, neither of these references teach the amplification process of the claimed invention.

Finally, the Patent Owner notes that, for substantially analogous reasons, these references do not disclose the invention of the originally presented claims, as properly construed in light of the prosecution history. *See* note 3, *supra*, and associated art.

D. Conclusion

For the foregoing reasons, the Patent Owner respectfully submits that claims 1-59 are in condition for allowance and earnestly requests early notification to this effect.

If there are any fees due in connection with the filing of this Preliminary Amendment not already accounted for, please charge the fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: Jean Burke Fordis
Jean Burke Fordis
Reg. No. 32,984

Dated: March 8, 2000

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS

This application is a divisional application of U.S. Ser. No. 08/400.657 filed Mar. 8. 1995; which is a continuation application of U.S. Ser. No. 08/257.469, filed Jun. 8. 1994 and now abandoned; which is a continuation application of U.S. Seral No. 08/124.826. filed Sep. 21. 1993 and now abandoned; which is a continuation application of U.S. Ser. No. 07/946.749 filed Sep. 17, 1992 and now abandoned; which is a continuation application of U.S. Ser. No. 07/648, 468 filed Jan. 31. 1991 and now abandoned; which is a continuation-in-part application of U.S. Ser. No. 07/136.920 filed Dec. 21. 1987 and now abandoned; and which is a continuation-in-part application of U.S. Ser. No. 06/922.155 filed Oct. 23. 1986 and now abandoned. The disclosures of Ser. No. 07/136.920 and 06/922.155 are incorporated herein by reference.

BACKGROUND OF THE INVENTION

The present invention pertains to methods. reagents. compositions. kits, and instruments for use in capturing target molecules. In particular, the present invention relates to methods. reagents. compositions, and kits for capturing deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) from clinical samples. Embodiments of the present invention provide methods for rapid, sensitive detection of nucleic acid targets in clinical samples adaptable to non-radioactive labeling techniques and automation.

The following definitions are provided to facilitate an understanding of the present invention. The term "biological binding pair" as used in the present application refers to any pair of molecules which exhibit natural affinity or binding capacity. For the purposes of the present application, the term "ligand" will refer to one molecule of the biological binding pair and the term "antiligand" or "receptor" will refer to the opposite molecule of the biological binding pair. For example. without limitation. embodiments of the present invention have applications in nucleic acid hybridization assays where the biological binding pair includes two complementary strands of polynucleic acid. One of the strands is designated the ligand and the other strand is designated the antiligand. However, the biological binding pair may include antigens and antibodies, drugs, and drug receptor sites and enzymes and enzyme substrates.

The term "probe" refers to a ligand of known qualities capable of selectively binding to a target antiligand. As applied to nucliec acids, the term "probe" refers to a strand of nucleic acid having a base sequence complementary to a target strand.

The term "label" refers to a molecular moiety capable of detection including, by way of example, without limitation, radioactive isotopes, enzymes, luminescent agents, and dyes. The term "agent" is used in a broad sense, including any molecular moiety which participates in reactions which lead to a detectable response. The term "cofactor" is used broadly to include any molecular moiety which participates in reactions with the agent.

The term "retrievable" is used in a broad sense to described an entity which can be substantially dispersed within a medium and removed or separated from the medium by immobilization, filtering, partitioning, or the like.

The term "support" when used alone includes conventional supports such as filters and membranes as well as retrievable supports.

The term "reversible," in regard to the binding of ligands and antiligands, means capable of binding or releasing upon imposing changes which do not permanently alter the gross chemical nature of the ligand and antiligand. For example, without limitation, reversible binding would include such binding and release controlled by changes in pH, temperature, and ionic strength which do not destroy the ligand or antiligand.

The term "amplify" is used in the broad sense to mean creating an amplification product which may include by way of example, additional target molecules, or target-like molecules which are capable of functioning in a manner like the target molecule, or a molecule subject to detection steps in place of the target molecule, which molecules are created by virtue of the presence of the target molecule in the sample. In the situation where the target is a polynucleotide, additional target, or target-like molecules, or molecules subject to detecting can be made enzymatically with DNA or RNA polymerases or transcriptases.

Genetic information is stored in living cells in threadlike molecules of DNA. In vivo, the DNA molecule is a double helix, each strand of which is a chain of nucleotides. Each nucleotide is characterized by one of four bases: adenine (A), guanine (G), thymine (T), and cytosine (C). The bases are complementary in the sense that, due to the orientation of functional groups, certain base pairs attract and bond to each other through hydrogen bonding. Adenine in one strand of DNA pairs with thymine in an opposing complementary strand. Guanine in one strand of DNA pairs with cytosine in an opposing complementary strand. In RNA, the thymine base is replaced by uracil (U) which pairs with adenine in an opposing complementary strand.

DNA consists of covalently linked chains of deoxyribonucleotides and RNA consists of convalently linked chains of ribonucleotides. The genetic code of a living organism is carried upon the DNA strand in the sequence of the base pairs.

Each nucleic acid is linked by a phosphodiester bridge between the five prime hydroxyl group of the sugar of one nucleotide and the three prime hydroxyl group of the sugar of an adjacent nucleotide. Each linear strand of naturally occurring DNA or RNA has one terminal end having a free five prime hydroxyl group ad another terminal end having a three prime hydroxyl group. The terminal ends of polynucleotides are often referred to as being five prime termini or three prime termini in reference to the respective free hydroxyl group. Complementary strands of DNA and RNA form antiparallel complexes in which the three prime terminal end of one strand is oriented to the five prime terminal end of the opposing strand.

Nucleic acid hybridization assays are based on the tendency of two nucleic acid strands to pair at complementary regions. Presently, nucleic acid hybridization assays are primarily used to detect and identify unique DNA or RNA base sequences or specific genes in a complete DNA molecule, in mixtures of nucleic acid, or in mixtures of nucleic acid fragments.

The identification of unique DNA or RNA sequences or specific genes within the total DNA or RNA extracted from tissue or culture samples may indicate the presence of physiological or pathological conditions. In particular, the identification of unique DNA or RNA sequences or specific genes, within the total DNA or RNA extracted from human or animal tissue, may indicate the presence of genetic diseases or conditions such as sickle cell anemia, tissue compatibility, cancer and precancerous states, or bacterial or

viral infections. The identification of unique DNA or RNA sequences or specific genes within the total DNA or RNA extracted from bacterial cultures or tissue containing bacteria may indicate the presence of antibiotic resistance, toxins, viruses, or plasmids, or provide identification between types of bacteria.

Thus, nucleic acid hybridization assays have great potential in the diagnosis and detection of disease. Further potential exists in agriculture and food processing where nucleic acid hybridization assays may be used to detect plant pathogenesis or toxin-producing bacteria.

One of the most widely used nucleic acid hybridization assay procedures is known as the Southern blot filter hybridization method or simply, the Southern procedure (Southern, E., *J. Mol. Biol. I*, 98, 503, 1975). The Southern procedure is used to identify target DNA or RNA sequences. This procedure is generally carried out sheets. The immobilized sample RNA or DNA is contacted with radio-labeled probe strands of DNA having a base sequence complementary to the target sequence carrying a radioactive moiety which can be detected. Hybridization between the probe and the sample DNA is allowed to take place.

The hybridization process is generally very specific. The labeled probe will not combine with sample DNA or RNA if the two nucleotide entities do not share substantial complementary base pair organization standard. Hybridization can take from three to 48 hours depending on given conditions.

However, as a practical matter there is always nonspecific binding of the labeled probe to supports which appears as "background noise" on detection. Background noise reduces the sensitivity of an assay. Unhybridized DNA probe is subsequently washed away. The nitrocellulose sheet is placed on a sheet of X-ray film and allowed to expose. The X-ray film is developed with the exposed areas of the film identifying DNA fragments which have been hybridized to the DNA probe and therefore have the base pair sequence of interest.

The use of radioactive labeling agents in conjunction with Southern assay techniques have allowed the application of nucleic acid assays to clinical samples. Radioactive decay is detectable even in clinical samples containing extraneous proteinaceous and organic material. However, the presence of extraneous proteinaceous and organic material may contribute to nonspecific binding of the probe to the solid support. Moreover, the use of radioactive labeling techniques requires a long exposure time to visualize bands on X-ray film. A typical Southern procedure may require 1 to 7 days for exposure. The use of radioactive labeling agents further requires special laboratory procedures and licenses.

The above problems associated with assays involving radioisotopic labels have led to the development of techniques employing nonisotopic labels. Examples of nonisotopic labels include enzymes, luminescent agents, and dyes. Luminescent labels emit light upon exitation by an external energy source and may be grouped into categories dependent upon the source of the exciting energy, including: radioluminescent labels deriving energy from high energy particles; chemiluminescent labels which obtain energy from chemical reactions; bioluminescent labels wherein the exciting energy is applied in a biological system; and photoluminescent or fluorescent labels which are excitable by units of electromagnetic radiation (photons) of infrared, visual or ultraviolet light. See, generally, Smith et al., *Ann. Clin. Biochem.*, 18: 53, 274 (1981).

Nonisotopic assay techniques employing labels excitable by nonradioactive energy sources avoid the health hazards

and licensing problems encountered with radioisotopic label assay techniques. Moreover, nonisotopic assay techniques hold promise for rapid detection avoiding the long exposure time associated with the use of X-ray film.

However, nonisotopic assays have not conveyed the sensitivity or specificity to assay procedures necessary to be considered reliable. In luminescent assays, the presence of proteins and other molecules carried in biological samples may cause scattering of the exciting light or may absorb light in the spectrum of emission of the luminescent label, resulting in a quenching of the luminescent probe.

In enzymatic assays, the presence of proteins and other molecules carried in biological samples may interfere with the activity of the enzyme.

Similarly, in colorimetric assays, the change in color may not be detectable over proteins and other materials carried in biological samples.

Embodiments of the present invention are concerned with target and background capture on supports and on retrievable supports including magnetic particles. Magnetic particles have been suggested as supports for the synthesis of organic compounds, including oligomers such as DNA, RNA, polypeptides, and other multiunit molecules that have a defined sequences. See, for example, European Patent Application No. 83112493.8 to Steven A. Benner and Genetics Institute. However, magnetic particles have not been suggested as retrievable supports for target capture and background removal.

Other utilization of magnetic particles has included magnetic fluids in the blood, R. Neubauer, *IEEE transactions on magnetics MAG-9*, 445 (1973); attachment of functional group for separation of biomolecules, U.S. Pat. No. 3,970, 518 to I. Giaver; labelling of cell-surface receptors, S. Margel et al., *Jour. Imm. Meth.* 28:341–53 (1979); attachment to drugs for magnetic targeting during therapeutic, A. Senyei et al., *J. App. Phys.*, 49 (6): 3578 (1978). K. Wieder et al., *Pro. Soc. of Exp. Bio. Med.*, 58:141 (1978), K. Mosbach and U. Shroeder, *FEBS letters* 102:112 (1979); selective separation of viruses, bacteria, and other cells, R. Molday et al., *Nature* 268:438 (1977); and incorporation of magnetic particles as support in gel affinity chromatography for biological polymers, K. Mosbach and L. Anderson, *Nature* 270:359 (1977), which are incorporated herein by reference.

The use of a two probe system to effect target capture on conventional non-retrievable supports has been suggested in an article authored by Ann-Christine Syuänen, Matti Laaksonen and Hans Söderlund entitled "Faster Quantification of Nucleic Acid Hybrids by Affinity-Based Hybrid Collection;" *Nucleic Acids Research*, 14(12): 5037 (1986).

SUMMARY OF THE INVENTION

It is an object of the present invention to provide methods, reagents, compositions, kits, and instrumentation for performing assays for target molecules of interest. Other objects will be presented hereinafter. For convenience, without limitation embodiments of the present invention can be grouped into areas of target capture, background capture, and combinations thereof.

Turning first to target capture, an embodiment of the present invention feature capture and release cycles to isolate target molecules. The method includes contacting a sample medium potentially containing target molecules with probes and a first support associated or capable of associating with at least one probe under binding conditions. The

probes are capable of selectively reversibly binding to the target molecules to form a complex including the probe target and the first retrievable support. Next, the support is separated from the sample medium and brought into contact with a second medium. Next, the support is subjected to releasing conditions to release the target from the support and the support is separated from the second medium. Next, a second support is contacted with the second medium under binding conditions. The second support is associated with or capable of associating with at least one probe capable of selectively binding to the target molecule. Under binding conditions, the target forms a complex with the probe associated to second support for further processing.

Preferably, the first support is retrievable in the sense that it is capable of substantially homogeneous dispersion within the sample medium and can be substantially physically separated, retrieved, or immobilized within the sample medium.

Separation of the first support from the first medium removes nonspecifically bound cellular debris attached to the first support. Further binding of the target molecule to a second support further concentrates the target for detection and permits further release-capture cycles for greater purification.

A further embodiment of the present method features a retrievable support. The method includes contacting the sample potentially carrying target nucleic acid with a retrievable support in association with a probe moiety. The retrievable support is capable of substantially homogenous dispersion within a sample medium. The probe moiety may be associated to the retrievable support, by way of example, by covalent binding of the probe moiety to the retrievable support, by affinity association, hydrogen bonding, or non-specific association.

The support may take many forms including, by way of example, nitrocellulose reduced to particulate form and retrievable upon passing the sample medium containing the support through a sieve; nitrocellulose or the materials impregnated with magnetic particles or the like, allowing the nitrocelulose to migrate within the sample medium upon the application of a magnetic field; beads or particles which may be filtered or exhibit electromagnetic properties; and polystyrene beads which partition to the surface of an aqueous medium.

A preferred embodiment of the present invention includes a retrievable support comprising magnetic beads characterized in their ability to be substantially homogeneously dispersed in a sample medium. Preferably, the magnetic beads carry primary amine or carboxyl functional groups which facilitate covalent binding or association of a probe entity to the magnetic support particles. Preferably, the magnetic support beads are single domain magnets and are super paramagnetic exhibiting no residual magnetism. The first probe includes a probe ligand moiety capable of specifically binding to antiligand under binding conditions. The retrievable support is capable of substantially homogeneous dispersion within the sample media and includes at least one antiligand moiety capable of binding to ligand under binding conditions to form a target-probe support complex. Next, the retrievable support and sample medium are separated to allow the sample medium to be processed further.

Embodiments of the invention are suitable for capturing target molecules from a clinical sample medium containing extraneous material. The order of contacting the sample medium with probe or retrievable support is a matter of choice. However, the choice may be influenced by the

kinetics of binding between the probe and target on one hand, and between the probe ligand and support antiligand on the other.

As applied to polynucleotide target molecules and homopolymer ligands and antiligands, the homopolymer ligand and antiligand binding is generally faster than probe binding to target. Probe binding to the target is sterically impaired after the probe ligand is bound to the support antiligand. A preferred embodiment includes contacting the sample medium with the reagent and bringing the mixture to hybridization conditions. Next, the retrievable support is dispersed in the reagent and sample medium allowing the formation of a target-probe complex in advance of the formation of probe support complexes.

A further embodiment of the present invention features a multiple probe system.

Preferably the method includes a reagent including a first probe as previously described and at least one second probe capable of binding to the target molecule and having label moieties capable of detection. The second probe is capable of forming a target (first and second) probe-support complex. The step of separating the retrievable support from the sample medium not only removes extraneous material from the target-(first and second) probe-support complex, but also separates any second probe which is not bound to the target. Second probe unbound to target contributes to background noises, false signals indicating the presence of target.

Further processing may include release of the target (first and second) probe complex from the retrievable support into a second medium and rebinding of the target (first and second) probe complex to new support. The first retrievable support may carry nonspecifically bound materials which can interfere with assay procedures. Thus, after the release of the target-probe complex from the retrievable support and the retrievable supports removal, a second support having an antiligand moiety capable of binding to the probe ligand can be brought into contact with the target-probe complex under binding conditions to effect a further cycle of target-probe binding or capture for further purification and concentration of target-probe complex.

Further processing may include background capture. A further embodiment of the present invention includes a method wherein the second probe has a second ligand moiety. The method further includes a background support having a second antiligand moiety. The second ligand moiety and second antiligand moiety are capable of stably binding under binding conditions only when the second probe is unbound to the target molecule. The method further includes the step of contacting a medium potentially containing second probe unbound to target with a background support under binding conditions. Next, the background support is separated from the medium to remove unbound second probe reducing background noise.

The term "background support" is used in the conventional sense to include filters and membranes as well as retrievable supports. Binding to the background support does not need to be releasible.

A preferred retrievable support includes, by way of example without limitation, particles, grains, beads, or filaments capable of dispersion within and separation from a medium. Methods of separation include by way of example, without limitation, of filtration, centrifugation, precipitation, surface floatation, settling, or the introduction of electromagnetic fields.

The present method can be applied to polynucleotide target molecules. Preferably, the first and second probes bind

quickly to a polynucleotide target "in solution" as opposed to the situation where either the target or probe is immobilized.

The retrievable support, capable of substantial dispersion within a solution, permits interactions between the retrievable support and probes which mimic "in solution" hybridization. In solution, hybridiation can be completed in approximately 3–15 minutes. The rapid hybridizations and simplicity of the present methods permit automation. The present method allows nucleic acid sequences contained in clinical samples to be separated from extraneous material allowing the methods to be applied to nonisotopic labeling techniques.

An embodiment of the present method where the target molecule is a polynucleotide, includes contacting a sample medium with reagent under binding conditions. The reagent includes at least one first polynucleotide probe and at least one second polynucleotide probe. The first probe is capable of forming a complex with the target molecule and has a first homopolymer ligand moiety. The second probe is capable of forming a complex with the target molecule in addition to the first probe. The second probe includes a label moiety which has a second homopolymer ligand moiety which is different than the first homopolymer ligand of the first probe. Next, the reagent and sample medium are contacted with a background support and a target capture support. The background support includes at least one second homopolymer antiligand moiety capable of binding to the second homopolymer ligand moiety of the second probe when said second probe is unbound to target. The target capture support includes at least one first homopolymer moiety capable of binding to the first homopolymer ligand moiety of the first probe. The background support and the target capture support remove background noise and the target capture support further concentrates the target-(first and second) probe complex for further processing and separates the target-(first and second) probe complex from cellular debris. Further processing includes the detection of the label moiety indicative of the presence of the target molecule.

Turning now more specifically to embodiments of the invention pertaining to background capture, one embodiment includes a method wherein probe and target are allowed to form a complex. Next, uncomplexed probe is brought into contact with a support under binding conditions. The support is capable of selectively binding unbound probe. Next, the support is separated from the probe-target complex.

A still further embodiment of the present invention includes a method of separating a plurality of target molecules for further processing.

One embodiment includes the sequential addition and removal of probes specific to target molecules on a plurality of supports. A further embodiment includes a method which includes contacting a sample with a first series probe and capturing the target and probe on a plurality of supports. The first series probe includes a ligand capable of association with the support. The first probe series includes probes for all plurality targets which are capable of binding to supports specific for each target molecule. The supports are capable of being separated from each other, the separation of which results in individual types of target molecules being isolated with the support.

A further embodiment of the present invention includes a reagent composition. The reagent composition includes a first probe and a second probe. The first probe is capable of forming a complex with a target molecule and includes a

probe ligand moiety capable of specifically binding to antiligand under binding conditions. The second probe is capable of forming a complex with the target molecule and includes a label moiety capable of detection. The reagent composition can be used to capture and detect the target in a sample medium when used with a retrievable support having antiligand moieties.

A further embodiment of the present reagent composition includes a second probe having a second ligand moiety capable of stably binding to an antiligand only in the situation where the second probe is unbound to the target molecule. The reagent composition allows background noise to be reduced by contacting sample potentially containing an unbound second probe with a background support having a second antiligand moiety.

A further embodiment includes a support capable of substantially homogeneous dispersion in a sample medium having oligonucleotide antiligands adapted for binding to oligonucleotide ligands on probes.

A preferred embodiment of the support includes, by way of example, particles, grains, filaments, and beads capable of separation. Means of separation include, by way of example without limitation, precipitation, settling, floatation, filtration, centrifugation, and electromagnetism.

A preferred embodiment includes polystyrene beads, between 10–100 microns in diameter, which are capable of substantially homogeneous dispersion and separation from a medium by filtration or floatation. Another preferred embodiment includes ferromagnetic beads. A ferromagnetic bead marketed under the trademarks BIO-MAG is capable of substantially homogeneous dispersion in an aqueous medium and can be retrieved or immobilized by an electromagnetic field. The ferromagnetic bead includes an iron core which is coated with an amine reactive covering. The beads are generally spherical and have a diameter of one micron. The polystyrene and ferromagnetic beads are treated to include antiligand moieties.

A further embodiment of the present invention includes a kit for performing assays for target molecules which are part of a biological binding pair. In the case where the target is a polynucleotide having a specific base sequence, the kit includes a reagent wherein the reagent includes a first polynucleotide probe and a second polynucleotide probe. The first and second probes are capable of binding to mutually exclusive portions of the target to form a complex in which both probes are bound to the target. The first probe is capable of reversibly binding to a first support under binding conditions, and the second probe includes a label moiety capable of detection. The kit further includes a first support allowing the support to form complexes with the target and probes which can be selectively separated from the sample medium.

A further embodiment of the present kit includes a second probe and a background support. The second probe, when not bound to the target, is capable of selectively binding to a background support. The background support is capable of being separated from a medium containing reagent to remove the nonspecifically bound second probe.

A further embodiment of the present invention includes an instrument for performing assays in accordance with the present method. In the situation where the target is a polynucleotide, the instrument includes a reaction chamber adapted for receiving reagent and target in a substantially mixed homogeneous state. The reagent includes a first and a second polynucleotide probe. Each probe is capable of binding to mutually exclusive portions of the target forming

a complex in which both probes are bound to the target. The first probe is capable of reversibly binding to a first support under binding conditions and the second probe includes a label moiety capable of detection. The instrument further includes means for contacting a first support with the reagent and sample to allow the first probe and target-probe complex to become bound to the support. The instrument further includes means for bringing the sample, reagent, and support to binding conditions to form target-probe complexes bound to support. The instrument further includes means for bringing the first probe into releasing conditions. Finally, the instrument includes means for separating the support from the sample and from the reagent.

The term "reaction vessel" is used in a broad sense to include any means of containment including, by way of example without limitation, cuvettes, test tubes, capillaries, and the like.

Suitable means for bringing the sample, reagent, and support into binding conditions or bringing reagent and support into releasing conditions include by way of example, temperature controls which can elevate or lower the temperature of the sample, reagent, and support to selective denature or anneal polynucleotide strands.

Suitable means for separating the support from the reagent or sample include by way of example, electromagnets for use in conjunction with magnetic beads, fibers affixed to an anchoring support, centrifuges for use with polystyrene grains, and the like.

Further embodiments of the present invention include means for bringing the reagent and target into contact with background support under binding conditions to remove any second probes having label moieties which second probes are not specifically bound to the target.

Embodiments of the present instrument adapted for use with luminescent label moieties include suitable label excitation means. Instruments for use with fluorescent label moieties include lasers or light emitting assemblies with filters to define appropriate wave lengths. Instruments for use with chemiluminescent label moieties include injection apparatus for injecting cofactors into the reaction chamber.

The invention also features a method for assaying a sample for a target polynucleotide, which sample contains the target polynucleotide and non-target polynucleotides, the method involving contacting the sample with a polynucleotide probe capable of forming a complex with the target polynucleotide, substantially separating the complex from the non-target polynucleotides in the sample, amplifying the target polynucleotide, to form an amplification product, and measuring or detecting the amplified target polynucleotide. This method advantageously can be used in conjunction with the target capture and background capture steps described above.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1–3 are flow diagrams illustrating steps, apparatus, and reagents used in methods of the invention. The term "FIG. 1" refers collectively to FIG. 1*a* and FIG. 1*b*. Similarly, the term "FIG. 2" refers collectively to FIG. 2*a* and FIG. 2*b*.

FIG. 4–6 are diagrammatic representations of capture amplification methods of the invention.

FIG. 7 is a diagram illustrating features of an apparatus made in accordance with one embodiment of the present invention.

FIG. 8 is a diagrammatic representation of a genetic construction used in the invention.

DETAILED DESCRIPTION

Turning now to the drawings, which by way of illustration depict preferred embodiments of the present invention, and in particular FIG. 1, a method of procedure, with necessary reagent compositions, is illustrated in schematic form for an assay for target polynucleotide strands. Conventional assay technique include many target strands, and many probe strands would be used to performs an assay. However, for the simplicity to further an understanding of the invention, the illustration depicts only limited numbers of probes, support entities, and targets. FIG. 1 features a method utilizing retrievable supports.

Step 1 of the assay illustrated in FIG. 1 begins with a clinical sample which, by way of illustration, contains cells. The cells potentially carry target nucleic acid, either DNA or RNA, having a base sequence of particular interest indicative of pathogens, genetic conditions, or desirable gene characteristics. The clinical samples can be obtained from any excreta or physiological fluid, such as stool, urine, sputum, pus, serum, plasma, ocular lens fluid, spinal fluid, lymph, genital washings, or the like. Individuals skilled in the art may desire to reduce biopsy samples to single cell suspensions or small clumps by means known in the art. For example, biopsy samples of solid tissues can be effectively reduced to single cell suspensions or to small clumps of cells by agitating the biopsy sample in a mixture of 0.5M sodium chloride, 10 mM magnesium chloride, 0.14M phosphate buffer, pH 6.8, and 25 Mg/ml cyclohexamide. Isolation of specific cell types by established procedures known in the art, such as differential centrifugation, density gradient centrifugation, or other methods, can also be applied at this step.

The cells are then treated to liberate their DNA and/or RNA. Chemical lysing is well known in the art. Chemical lysing can be performed with the dilute aqueous alkali, for example, 0.1 to 1.0M sodium hydroxide. The alkali also serves to denature the DNA or RNA. Other denaturization and lysing agents include elevated temperatures, organic reagents, for example, alcohols, amides, amines, ureas, phenols and sulfoxides, or certain inorganic ions, for example chaotropic salts such as sodium trifluoroacetate, sodium trichloroacetate, sodium perchlorate, guanidinium isothiocyanate, sodium iodide, potassium iodide, sodium isothiocyanate, and potassium isothiocyanate.

The clinical sample may also be subjected to various restriction endonucleases to divide DNA or RNA into discrete segments which may be easier to handle. At the completion of the sample processing steps, the clinical sample includes sample nucleic acid, cellular debris, and impurities. In the past, sample nucleic acid was separated from cellular debris and impurities by nonspecific binding of the nucleic acid to filters or membranes and washing cellular debris and impurities from the filter or membrane. However, in practice, some cellular debris and some impurities, as well as nontarget nucleic acid, are nonspecifically bound to the filter or membrane and are not removed by washes.

An embodiment of the present invention, as illustrated in Step 1, includes contacting the sample potentially carrying target nucleic acid with a retrievable support in association with a probe moiety. The retrievable support is capable of substantially homogenous dispersion within a sample medium. The probe moiety may be associated to the retrievable support, by way of example, by covalent binding of the probe moiety to the retrievable support, by affinity association, hydrogen binding, or nonspecific association.

The support may take many forms including, by way of example, nitrocellulose reduced to particulate form and

retrievable upon passing the sample medium containing the support through a sieve; nitrocellulose or the materials impregnated with magnetic particles or the like, allowing the nitrocellulose to migrate within the sample medium upon the application of a magnetic field; beads or particles which may be filtered or exhibit electromagnetic properties; and polystyrene beads which partition to the surface of an aqueous medium.

A preferred embodiment of the present invention includes a retrievable support comprising magnetic beads characterized in their ability to be substantially homogeneously dispersed in a sample medium. Preferably, the magnetic beads contain primary amine functional groups which facilitate covalent binding or association of a probe entity to the magnetic support particles. Preferably, the magnetic support beads are single domain magnets and are super paramagnetic exhibiting no residual magnetism.

The particles or beads may be comprised of magnetic particles, although they can also be other magnetic metal or metal oxides, whether in impure, alloy, or composite form, as long as they have a reactive surface and exhibit an ability to react to a magnetic field. Other materials that may be used individually or in combination with iron include, but are not limited to, cobalt, nickel, and silicon. Methods of making magnetite or metal oxide particles are disclosed in Vandenberghe et al., "Preparation and Magnetic Properties of Ultrafine Cobalt Ferrites," *J. of Magnetism and Magnetic Materials*, 15 through 18: 1117–18 (1980); E. Matijevic, "Mono Dispersed Metal (Hydrous) Oxide—A Fascinating Field of Colloidal Science," *Acc. Chem. Res.*, 14:22–29 (1981), the disclosures which are incorporated herein by reference.

A magnetic bead suitable for application to the present invention includes a magnetic bead containing primary amine functional groups marketed under the trade name BIO-MAG by Advanced Magnetics, Inc. A preferred magnetic particle is nonporous yet still permits association with a probe moiety. Reactive sites not involved in the association of a probe moiety are preferably blocked to prevent nonspecific binding of other reagents, impurities, and cellular material. The magnetic particles preferably exist as substantially colloidal suspensions. Reagents and substrates and probe moieties associated to the surface of the particle extend directly into the solution surrounding the particle. Probe moieties react with dissolved reagents and substrates in solution with rates and yields characteristic of reactions in solution rather than rates associated with solid supported reactions. Further, with decreasing particle size the ratio of surface area to volume of the particles increases thereby permitting more functional groups and probes to be attached per unit weight of magnetic particles.

Beads having reactive amine functional groups can be reacted with polynucleotides to covalently affix the polynucleotide to the bead. The beads are reacted with 10 percent glutaraldehyde in sodium phosphate buffer and subsequently reacted in a phosphate buffer with ethylene-diamine adduct of the phosphorylated polynucleotide in a process which will be set forth in greater detail in the experimental protocol which follows.

Returning now to Step 2, the retrievable support with associated probe moieties is brought into contact with clinical sample and, progressing through to Step 3, is brought into binding conditions. The probe moiety specific for the target of interest becomes bonded to the target strands present in the clinical sample. The retrievable support, dispersed throughout the sample and reagent medium,

allows the probe moieties and target to hybridize as though they are free in a solution.

Hybridizations of probe to target can be accomplished in approximately 15 minutes. In contrast, hybridizations in which either the probe or target are immobilized on a support not having the capability to be dispersed in the medium may take as long as 3to 48 hours.

Extraneous DNA, RNA, cellular debris, and impurities are not specifically bound to the support. However, as a practical manner, a small amount of extraneous DNA, RNA, cellular debris, and impurities are able to and do in fact nonspecifically bind to any entity placed within the reaction vessel including the retrievable support. Embodiments of the present invention facilitate the further purification of clinical samples to remove extraneous DNA, RNA, cellular debris, and further impurities from target polynucleotides.

Step 4 of FIG. 1 depicts the separation of the support of the clinical sample and the suspension of the support into a second medium. The second medium thus includes the retrievable support with the associated probe bound to target polynucleotide strands. Also carried with the retrievable support is extraneous DNA, RNA, cellular debris, and impurities nonspecifically bound to the support, but in a much lower concentration than what was initially found in the clinical sample. Those skilled in the art will recognize that some undesirable materials can be reduced by washing the support prior to suspension in the second medium.

The retrievable support with associated probe and target strands suspended in the second medium is subject to further denaturation as set forth in Step 5 thereby allowing the target to disassociate from the probe moieties of the retrievable support. The denaturation process may or may not release nonspecifically bound extraneous DNA, RNA, cellular debris, or impurities from the retrievable support. However, Step 5 of the present method allows the retrievable support to the removed from the second medium carrying with it much of the nonspecifically bound cellular debris, impurities, and extraneous DNA, and RNA initially carried over from the first clinical sample medium.

As set forth in Step 6, a new support can be introduced into the second medium under binding conditions to again capture target polynucleotide strands on probe moieties associated with the retrievable support. It will be recognized by those skilled in the art that the new support may actually include the original retrievable support after recycling steps to further purify and remove nonspecifically bound DNA, RNA, cellular debris, and impurities. Thus, the only impurities present in the second medium include DNA, RNA, cellular debris, and impurities previously nonspecifically bound to the support which has subsequently been released from the first support and dissolved or suspended in the second medium.

However, such impurities can be further removed from the target polynucleotides by removing the second retrievable support from the second medium and again repeating the cycle of introducing the retrievable support into a further medium, denaturation, and removal of the old support. Those skilled in the art will recognize that the magnetic beads described in the present invention are susceptible of being raised out of a solution or being held in place as a solution is removed or added to a containment vessel.

The ability of the magnetic beads to participate in the reactions which mimic "insolution kinetics" strands allow the completion of a cycle of denaturation and binding to the target to be accomplished in three to fifteen minutes.

After sufficient purification and concentration, the target can be detected by luminescent or radioactive methods

known in the art as indicated in Step 8. Purification of the medium containing the target allows the detection of nonisotopic label moieties without cellular debris and impurities.

Turning now to FIG. 2, which features a multiple probe method, a further embodiment to the present assay method is illustrated beginning with a clinical sample containing polynucleotide target which is processed in accordance with the clinical sample of the previous figure with the introduction of solubilizing agents and reagent. The reagent of the assay method depicted in FIG. 2 includes a first polynucleotide probe strand (P_1) and a second polynucleotide probe strand (P_2) capable of forming a complex with the target in which both probes (P_1 and P_2) are bound to the target. The first probe (P_1) is capable of associating with a retrievable support (S_1) under binding conditions. The second probe has at least one label moiety capable of detection. The label moiety is illustrated in the drawings with an asterisk or a star. Following the introduction of a solubilizing agents and reagent under denaturation conditions, the solution containing the clinical sample potentially includes target polynucleotides and reagent in the form of the first and second probes, plus cellular debris, solubilizing agents, impurities, and extraneous RNA and DNA.

Under binding conditions as illustrated in Step 2, the first and second probes ($P_1$and P_2) bind to mutually exclusive portions of the target. The hybridization of the probes (P_1 and P_2) to the target in solution is rapid and unimpaired by association with a solid support. In order to insure the binding of the target to the first and second probe strands (P_1 and P_2) an excess of probe is employed. However, even if an excess of probe (P_1 and P_2) were not employed, some probe would fail to find target and would remain unhybridized in the sample medium. The unhybridized second probe (P_2) having a label moiety constitutes background noise if present during detection.

The first probe (P_1) is capable of binding to a support (S_1) by means of a ligand capable of binding to an antiligand moiety on a support. The ligand (L_1) includes, by way of example, a tail portion comprising a homopolymer. The support (S_1) includes an antiligand (A_1) capable of receiving and binding to ligand (L_1). The antiligand (A_1) includes, by way of example, a homopolymer complementary to the ligand (L_1) of probe (P_1).

Turning now to Step 3, under binding conditions the antiligand moiety (A_1) of support (S_1) associates or binds to the ligand moiety (L_1) of the first probe (P_1) which is itself bound to the target and linked to the second probe (P_2). The support may take many forms. Beads or particulate supports can e dispersed in solution and participate in binding with target probe reactions which demonstrate near in solution kinetics. Further, retrievable beads and particulate supports can separate probe-target complexes from nondissolvable debris without clogging problem inherent in more conventional filters or membranes.

However, conventional membranes, filters, or cellulose supports may also be employed for some applications in which clogging may not be a problem. Due to the rapid hybridization of the probes to target insolution, a solid nonbead or nonparticulate membrane or filter support can be incorporated into the reaction vessel. The solution of reagent and sample can be passed through the support to affect target capture. The support (S_1) is illustrated in FIG. 2 as a retrievable support.

In solution with the target-probe support complex are unbound first and second probe moieties, unbound target solubilizing agents, impurities, and cellular debris. The

unbound second probe (P_2) which has label moieties constitutes noise, producing a signal which mimics the presence of target. A small amount of extraneous cellular debris, solubilizing agents, impurities, and probes may also become nonspecifically bound to the retrievable support.

In Step 4, the support (S_1) is separated from the clinical sample medium. If a retrievable support is used, separation can be accomplished either by immobilizing the retrievable support within a reaction vessel or by withdrawing the retrievable support from the sample medium directly. Those skilled in the art will recognize that the immobilized support can be washed to reduce undesirable material.

Turning now to Step 5, the target-probe support complex is substantially free of extraneous RNA, DNA, solubilizing agents, impurities, and cellular material and can be monitored for the presence of the label moieties indicative of the presence of the target molecule. However, a small amount of extraneous DNA, RNA, solubilizing agents, impurities, and cellular materials may still be nonspecifically bound to the support (S_1). Moreover, unbound, in the sense that it is not associated with target, second probe (P_2) may also be nonspecifically bound to the support (S_1) and can affect signals from nonisotopic label moieties. The presence of unbound second probe moiety (P_2) having label moieties is a significant cause of background noise thereby reducing the accuracy of the assay procedure.

Thus, as an alternative Step 5, the first support (S_1) may be suspended into a second medium where the support (S_1) is separated from the target-probe complex by denaturation.

Following denaturation, in Step 6, the first support (S_1) is removed from the second medium and replaced with a second support (S_2). The second support (S_2) includes an antiligand moiety (A_1) capable of binding to the ligand moiety (L_1) of the first probe.

Moving to Step 7, under binding conditions, the target-probe complex reassociates with the second support (S_2). The removal of the first support (S_1) removes extraneous material, debris, and probes nonspecifically bound to the first support (S_1) from the assay medium.

As illustrated in Step 8, the medium containing the target-probe complex can be monitored for the presence of the labels. However, further purification of the assay medium can be performed to further reduce the presence of background and extraneous materials which may have been carried from the sample medium nonspecifically bound to the first retrievable support (S_1) and subsequently dissolved or disassociated from the first support (S_1) into the second medium.

Thus, the second retrievable support (S_2) may be brought into contact with a third medium, the medium brought into conditions to release the target-probe complex from the support, and the support removed to complete a further cycle. The number of cycles will be a matter of choice depending on the type of sample, type of label moieties, and the sensitivity of the detection equipment. Different types of supports may be used at different times. Thus, a retrievable support can be used to gather or concentrate the target-probe complexes from sample mediums or solutions initially to avoid problems of clogging typical of membranes or filters. The second or third supports preferably includes a membrane or filter with antiligand moieties (A_1) which bind to the ligand moiety (L_1) of the first probe (P_1). Membrane or filter supports can simplify process steps allowing flow-through recovery of target-probe complexes.

A further embodiment of the present invention is particularly well suited for reducing background noise. Referring

now to FIG. 3, a modification of the previous assay procedure illustrated in FIG. 2 is described. In FIG. 3, a target polynucleotide has formed a complex with a first and second probe moiety (P_1 and P_2) similar to the probe moieties described in FIG. 2. However, the second probe includes a second ligand (L_2). The second ligand (L_2) may include, by way of example, a single terminal ribonucleotide which complexes with a borate antiligand, an alternating copolymer which binds with a complementary copolymer, a biotin ligand which binds to an avidin antiligand, or as illustrated, homopolymer ligand (L_2), and a complementary homopolymer antiligand (A_2).

Turning now to Step 1, a background support capable of selectively binding to the second probe (P_2), only when it is not bound to a target, is brought into contact with the medium containing the target-probe complex. The medium further includes free, disassociated first and second probes (P_1 and P_2). The labeled second probe (P_2), which contributes to the background noise, is specifically bound to the background support (B_1) by a vast molar excess of antiligand moieties (A_2) associated with the background support (B_1). Following binding of the unbound labeled probe (P_2) to the background support (B_1), the background support (B_1) is removed from the medium as illustrated in Step 2. The medium containing the target-probe complex can be monitored for the presence of the label contained upon the second probe (P_2) with a reduction in background noise. Alternatively, the medium containing the target-probe complex can be subjected to further processing.

The further processing can include further background reduction by repeating Steps 1 and through 3 described in FIG. 3 or, steps previously described in conjunction with FIG. 2. For example, background reduction steps can be incorporated into the processing of a clinical sample as illustrated in FIG. 2 at any point in which the ligand and antiligand moieties of the first and second probes do not interfere, and the target is complexed with the first and second probes.

An embodiment of the present method can practiced with additional amplification steps to generate an amplification product to improve the sensitivity of the assay. Turning now to FIGS. 4, 5, and 6, each Figure includes a Step 1 wherein target is captured with the use of a capture probe and a retrievable support in the form of a bead. The polynucleotide target includes areas defined as a^1, b^1, and c^1. The polynucleotide probe includes an area, "a" capable of binding to its complement "a^1" of the target. The probe further includes a ligand capable of binding to an antiligand associated with the bead. As illustrated, the ligand of the probe and the antiligand of the bead are complementary homopolymers.

In Step 2 of FIGS. 4, 5, and 6, the target is separated from extraneous polynucleotides, impurities, cellular material, and solubilizing reagents from sample processing procedures.

In Step 3 of FIGS. 4, 5, and 6, the isolated target is non-specifiably amplified to form a multitude of amplification products.

FIG. 4, Step 3, depicts amplification of the target DNA to form an amplification product subject to detection, complementary RNA, through the enzyme, core RNA polymerase. In FIG. 4, Step 3, the capture probe is complexed or coated with recA protein to facilitate probe target binding. Core RNA polymerase forms RNA complementary to the DNA target template. As the enzyme reads through the target sequences, the RNA probe area "a" and subsequent new nucleotide sequences are removed from the target which is

able to bind to new recA coated probes to form a multitude of RNA polynucleotides having an area "c" which can be detected. The integer "n" represents a plurality of amplification products.

In the situation where the target is RNA, such as ribosomal RNA (rRNA) or messenger RNA (mRNA) the target RNA can be replicated nonspecifically by denaturing the RNA and subjecting the RNA to an enzyme such as Qβ replicase or reverse transcriptase.

FIG. 5 illustrates the application of a two enzyme amplification system. In Step 3(a) of FIG. 5, DNA polymerase is used in conjunction with hexamer primers to generate DNA segments which are complementary to the target. In Step 3(b), core RNA polymerase is used to form additional RNA complements to both target DNA and DNA target complements.

FIG. 6 illustrates the application of an enzymatic amplification system based on the enzyme DNA polymerase. Thus, in step 3(a), the target, separated from extraneous polynucleotides, impurities and debris, is subjected to DNA polymerase in conjunction with non-specific hexamer primers. The DNA polymerase generates DNA segments which are complementary to the initial target. The new DNA product, formed from the target DNA, is also a substrate for replication. The target and complements are subjected to cycling steps to denature the target and target complements and to add new enzyme to create new copies of the target and the target complement.

Following formation of the enzyme product, Step 4 of FIGS. 4–6 illustrates capture of the target and/or enzyme product as previously described with a further probe and support. The target and/or enzyme reaction product are amenable for further process steps including detection.

An embodiment of the present methods may be practiced with an aid of apparatus set forth in schematic form in FIG. 7. The apparatus includes the following major elements: at least one containment vessel, means for controlling the association of a probe with a target molecule and a retrievable support, means for separating the retrievable support from a sample solution, and means for releasing the target molecule from the retrievable support. These major elements may take various forms and are described more fully below.

The apparatus will be described below for illustration purposes as applying the methods described in FIGS. 2 and 3 relative to a target molecule which includes a polynucleotide. Thus, at Station 1, a clinical sample is placed within the containment vessel with solubilizing agents such as chaotropic salts, enzymes, and surfactants in order to dissolve cellular material and release nucleic acids. The containment vessel may include agitation elements to facilitate the break up of cells. The containment vessel may include any type of vessel, tube, cuvette suitable for containing the sample.

In an instrument designed for automated analysis, the apparatus set forth in FIG. 7 will preferably include means for receiving a plurality of containment vessels. For illustration purposes, the containment vessels containing the sample are analyzed sequentially. Thus, containment vessels are conveyed to a first station and then to subsequent stations where various steps of the assay method are performed.

The various stations are linked by conveying means. Conveying means may include a rotatable turntable, conveying belt, or the like. As applied in a clinical hospital setting, conveying means may include manual movement. Thus, hospital staff may obtain a tissue sample from a

patient and place the sample in the containment vessel. Sample processing, including the breakup of the tissue sample and initial mixing of solubilizing agents and reagents would be initiated at bedside and continued as the containment vessel traveled to a subsequent station for further processing. Reference to stations are for illustration purposes. Those skilled in the art will recognize that certain stations or steps may be combined or reversed.

Returning now to the first station, sample and solubilizing agents are placed within a containment vessel in which an agitation element thoroughly mixes the sample and solubilizing agents, releasing nucleic acids from cellular materials. Conveying means carry the containment vessel to Station 2 where the containment vessel receives reagent.

The reagent includes a first polynucleotide probe and a second polynucleotide probe. The first and second probes are capable of forming a complex with the target polynucleotides in which both probes are bound to mutually exclusive portions of the target. The first probe is also capable of binding to a retrievable support under binding conditions. The second polynucleotide probe includes a label moiety capable of detection. The reagent and sample nucleic acid are denatured by a heating element and conveyed to Station 3.

At Station 3, the containment vessel receives a first support depicted by open circles. The first support is homogeneously dispersed within the sample medium by suitable means including an agitation element. Examples of suitable supports include, without limitation, polystyrene beads, magnetic beads and other particulate or filamentous substances. As illustrated, the first support includes a magnetic bead having polynucleotide antiligands of deoxythymidine (dT). The first probe includes a tail portion of deoxyadenosine (dA) capable of binding to the first support during binding or hybridization conditions.

Moving to Station 4 hybridization conditions are imposed upon the sample medium by cooling by a cooling element. However, those skilled in the art will recognize that means to alter salt concentrations can be readily substituted for thermal controls. Thus, the target polynucleotide forms a complex with the first and second probes. Further, the homopolymer deoxyadenosine (dA) tail portion of the first probe hybridizes to the deoxythymidine (dT) homopolymer of the retrievable support.

From Station 4, the containment vessel is moved to Station 5 where the retrievable support is immobilized on the wall of the containment vessel by activating a magnetic element. If polystyrene beads were substituted for magnetic beads, the polystyrene bead would be immobilized by filtering or density differences. The sample medium is disposed of carrying with it most of the extraneous DNA, RNA, solubilizing agents, cellular material, and impurities. The immobilized retrievable support is washed to further remove extraneous DNA, RNA, solubilizing agents, cellular materials, and impurities.

Further, although it is illustrated that the retrievable support is immobilized on the wall of the reaction vessel, it is also possible to remove the retrievable support from the reaction vessel by a magnetic element and dispose of the first reaction vessel containing with it extraneous DNA, RNA, solubilizing agents, and cellular material which may be nonspecifically bound to the reaction vessel walls.

The retrievable support is placed in a second medium, either the same containment vessel or a new containment vessel. The containment vessel, containing the retrievable support in a second medium is carried to Station 6.

At Station 6, the second medium is brought to denaturization conditions by suitable means including a heating element. The denaturization process releases the target-first and second-probe complex from the (dT) homopolymer of the retrievable support. The first support, potentially carrying extraneous DNA, RNA, impurities, and cellular material, is removed from the second medium. If desired, amplification steps may be applied to the target, now substantially free of impurities, debris, and non-target polynucleotides. Amplification steps may include the generation of an amplification product with enzymes such as, by way of example, DNA polymerase, RNA polymerase, transcriptases, or Qβ replicase. In the event the amplification product is not the target molecule, the second probe is directed to the amplification product as well as a third capture probe which takes the place of the first probe. A background support is then brought into contact with the second medium and passed to Station 7.

At Station 7 a cooling element brings the second medium to hybridization temperatures. The background support includes a second antiligand capable of specifically binding to a ligand carried upon the second probe. For example, without limitation, a terminal nucleotide of the second probe can be synthesized to be a ribo derivative which specifically binds to borate moiety carried upon the second support. The second probe bound to the target as part of a probe target complex will not bind to the borate carried upon the third support due to stearic hindrances. However, unbound second probe will specifically bind to the borate support. Alternatively, the second probe may include a homopolymer such as deoxycytosine (dC) which binds to a deoxyguanine (dG) homopolymer linker on a second support. The length of the homopolymers are designed such that complexes of the target-first and second probes with the second support are not stable; however, complexes of the second probe alone with the second support are stable within reaction parameters. Indeed, background capture binding of background support to unbound second probe can be irreversible.

Next, the containment vessel containing the second medium and the background support is conveyed to Station 8 where the background support having second probe strands unbound to the target-probe complex is separated from the second medium. Separation of the background support removes nonspecific background noise from the medium.

As illustrated, background capture is effected upon beads. However, those skilled in the art will recognize that the initial purification of the target-first and second probe complex from the clinical sample, removes all or most solid debris allowing background capture on filter or membrane supports through which the second medium can be flushed.

From Station 8, the purified medium containing the target-probe complex with reduced background is conveyed to Station 9. At Station 9, a third support, depicted as a membrane or filter, is brought into contact with the second medium which is brought to hybridization temperatures by a heating element. The third support includes first antiligand moieties which bind to the first ligand moieties of the first probe, or if an amplification product is generated in previous steps, to a first ligand moiety of a third probe directed to the amplification product. Thus, if the first ligand moiety of the first probe is of a homopolymer of deoxyadenosine (dA), the third support may include homopolymer of deoxythymidine (dT). As illustrated, the third support includes filters or membranes through which the second medium can be flushed; however, beads or particles may also be used. The third support serves to further concentrate the target-first and

5,565,322

second probe complex and permits further reduction of background and interfering materials which do not specifically bind to the third support. Moving to Station 10, the third support concentrates the target-first and second probe complex allowing detection of label moieties carried upon the second probe.

The present invention is further described in the following typical procedures and experimental examples which exemplify features of the preferred embodiment.

I. PROCEDURES

A. Materials

All reagents were of analytical grade or better. Magnetic beads marketed under the trademark BIO-MAG containing functional amino groups were obtained from Advanced Magnetics, Inc. of Cambridge, Mass.

In the present example, all labeled nucleotides were obtained from New England Nuclear. The enzyme terminal deoxynucleotidyl transferase (TDT) was obtained from Life Sciences, Inc., St. Petersburg, Fla. The oligonucleotide pdT_{10} was obtained from Pharmacia PL Biochemicals.

B. Synthesis of Probes

The following sets forth typical protocols and methods. Referring now to FIG. 8, two probes were constructed to the sense strand of the enterotoxin gene elt Al of *Escherichia coli*, in accordance with the constructional map, FIG. 8, of Spicer, E. K. and J. A. Noble, 1982. *J. of Biological Chem.* 257, 55716–55751.

One set of probes was synthesized beginning at position 483 of the gene sequence and extending onward 30 nucleotides in length, hereinafter referred to as the A483 probe. A second probe was synthesized beginning at position 532 in the gene sequence and extending 30 nucleotides in length, hereinafter referred to as the A532 probe. A third probe was synthesized beginning at position 726 in the gone sequence and extending 39 nucleotides in length, hereinafter referred to as the A726 probe. The specific base sequences (5' to 3') are set forth in Table 1 below:

TABLE I

Probe	Sequence
A483	AGA CCG GTA TTA CAG AAA TCT GAA TAT AGC
A532	AGA TTA GCA GGT TTC CCA CCG GAT CAC CAA
A726	GTC AGA GGT TGA CAT ATA TAA CAG AAT TCG GGG GGG GGG

The probes were synthesized by methods available in the art. The numbering system is adapted from the 768 nucleotide sequence available through Intelligenetics sequence bank ECO ELT Al.

Of the ten G residues at the 3 prime end of probe A726, three guanine bases towards the 5' end are capable of binding to three complementary cytosine bases of the tox gene. Stretches of three cytosines are common in DNA. The ten guanine bases form a ligand capable of binding to a poly C antiligand carried upon a support such as oligo dC-cellulose. However, seven guanine bases will not form a stable association with a support at 37° C., particularly if the probe is bound to target due to steric hindrance and the size of the target-probe complex. Probe A726 was modified by the random addition of approximately three residues of ^{32}P-dC and ^{32}P-dG to its 3' end with terminal transferase.

Those skilled in the art will recognize that other probes can be readily synthesized to other target molecules.

C. Preparation

The target in Example Nos. 1, 2 and 3 is the enterotoxin gene elt Al. The enterotoxin gene elt Al is carried as part of the plasmid EWD-299 obtained from Stanford University.

In Example No. 1, enterotoxigenic bacteria were grown to log-phase in Luria broth. The enterotoxigenic bacteria were lysed and the plasmid EWD-299 isolated. The plasmid EWD-299 was further digested with the restriction enzymes Xba 1 and Hind III. A fragment of 475 base length was used as target and purified by electro-elution from a 1 percent agarose gel. In order to follow the efficiency of capture steps, the fragment was 5' end labeled with ^{32}P-ATP with the enzyme polynucleotide kinase following manufacturer's instructions.

In Example Nos. 2 and 3, the enterotoxigenic bacteria and wild type nonenterotoxigenic *E. coli* JM83 were separately grown to log phase. The wild type *E. coli* serves as a control. Separate extracts of enterotoxigenic bacteria and wild type bacteria were prepared by substantially solubilizing the cells in chaotropic solutions. Thus, the bacteria cultures, in Luria broth, were added to solid guanidinium thiocyanate (GuSCN) to a concentration of 5M GuSCN. Tris-HCl to a concentration of 0.3M, and EDTA (pH7) to a concentration of 0.1M. The chaotropic-bacterial solutions were then heated to 100° C. for five minutes and cooled. The resultant enterotoxigenic bacteria extract was serially diluted with wild type nonenterotoxigenic bacteria extract. The concentration of tox plasmids per cell and the cell number in the extracts were measured by conventional techniques. The original extracts solubilized in GuSCN contained approximately 10^9 enterotoxigenic *E. coli* per ml and 100 plasmids/cell.

D. Synthesis of Beads

Retrievable supports were prepared from magnetic beads. Other retrievable supports include particles, fibers, polystyrene beads or other items capable of physical separation from a medium. Magnetic beads were synical separation from a medium. Magnetic beads were synthesized with an adduct of deoxythymidine of ten base length to allow the beads to associate with probes tailed with deoxyadenosine in a readily reversible manner.

Thus, 100 ml of beads having amine functional groups such as BIO-MAG (M4100) beads were washed four times with 20 mM sodium phosphate (pH 6.7) in four 275 ml T-flasks. The beads were then washed with 1% glutaraldehyde in 20 mM sodium phosphate. Next, the beads were reacted in 100 ml of 10 percent glutaraldehyde in 20 mM sodium phosphate (pH 6.7) for three hours at room temperature. The beads were then washed extensively with 20 mM sodium phosphate (pH 6.7) and then washed once with 20 mM phosphate (pH 7.6).

Separately, a purified ethylene diamine (EDA) adduct of pdT_{10} (EDA-dT_{10}) was prepared in accordance with Chu, B. C. F., G. M. Wahl, and L. E. Orgel; Nucleic Acid Res. 11,

6513–6529 (1983) incorporated by reference herein. The concentration of EDA-dT_{10} was adjusted to 1 OD/ml in 20 mM phosphate (pH 7.6).

The EDA-dT_{10} was combined with the magnetic beads to allow the EDA-dT_{10} to react with the free aldehyde groups of the beads. The mixture of EDA-dT_{10} and beads was divided into a plurality of 50 ml polypropylene tubes. The tubes containing the reaction mixture and beads were placed in a tube rotator and agitated overnight at room temperature.

Next, the beads were washed five times to remove non-covalently bound EDA-dT_{10} with a wash solution of sterile 20 mM phosphate (pH 6.7) in large 275 ml T-flasks and diluted to 200 ml with the wash solution.

For storage, beads can be maintained for months in a buffer of 20 mM phosphate, to which is added sodium azide to 0.1% and SDS to 0.1%. Bead preparations are stored at 4° C. protected from light.

The beads were then prehybridized to block nonspecific binding sites in a buffer, hereafter referred to as "prehybridization buffer", of 0.75M sodium phosphate (pH 6.8), 0.5% sodium lauroyl sarcosine, 10 micrograms/ml *E. coli* DNA, 0.5 milligram per milliliter mg/ml bovine serum albumin (BSA) (Nuclease-free) and 5 mM ethylenediaminetetraacetic acid) (EDTA). Before applying the probes and beads to target capture procedures, two prehybridizations of the beads were performed. The prehybridization procedure included placing the beads in ten volumes prehybridization buffer.

The first prehybridization procedure was performed with agitation at 60° C. The second prehybridization procedure was performed at room temperature with swirling. A 0.1 percent isoamyl alcohol solution was added to the solutions as a defoamant.

The binding capacity of dT_{10}-derivatized beads was measured by the following procedure. In separate vessels, dT_{50} and dA_{50} were 5' end labeled with ^{32}P-dT and ^{32}P-dA respectively to a specific activity (Sa) of about 10^6 dpm/microgram. Next, the Sa was accurately measured for a known quantity of reacted dT_{50} by trichloroacetic acid precipitation.

Next, 5 μg of ^{32}P-dA_{50} and 5 μg of ^{32}P-dT_{50}, having substantially identical Sas of between 100,000–200,000 dpm/mg, were separately added to tubes containing prehybridization buffer and brought to a volume of 1 ml.

A known sample volume of prehybridized beads was placed into four tubes. Two of the four tubes each receive 0.5 ml of the ^{32}P-dA_{50} mixture and the remaining two tubes receive 0.5 ml of the ^{32}P-dT_{50} mixture. All four solutions are brought to hybridization conditions for five minutes. The beads are thereafter immobilized and washed. The activities of the solutions are then monitored. The total binding capacity, C, for a quantity of bead preparation measured in micrograms is set forth below:

$$C=V(A-T)X$$

In the above equation X is the specific activity of ^{32}P-dT_{50} in cpm/mg, V is the volume ratio of total volume to sample volume, A is the average activity of the beads suspended in ^{32}P-dA solutions in cpm, and T is the average activity of the beads suspended in ^{32}P-dT solutions in cpm.

Those skilled in the art will recognize that other beads, particles, filaments, and the like can be formulated with other nucleotide combinations or homopolymers. For example, polyA-derivized beads were produced by substi-

tuting (for the purified EDA adduct of dT_{10}) a solution containing 100 mg poly A (mw>100.000) in 50 ml of 20 mM sodium phosphate (pH7.6).

E. Target Capture Procedures

Bead preparations were used to capture target polynucleotides. The following sets forth a typical experimental target capture protocol demonstrating retrievable supports and reversible captures for purposes of illustration, without limitation, the procedure will be discussed using a first probe A483 and a second probe A532. The first probe, A483, was randomly 3' end labeled with ^{32}P-dCTP and ^{32}P-dGTP to a specific radioactivity of about 10^{10} dpm/mg. The second probe, A532, was trailed with about 70 unlabeled dA residues by the enzyme terminal transferase.

First, 200 µg/ml of labeled probe A483 and 400 µg/ml of tailed probe A532 were mixed with varying amounts of a heat-denatured 475 me Xba 1-HIND III restriction fragment of the enterotoxin gene at 65° C. for 15 minutes in 1.4M sodium chloride.

Next, target capture was initiated by contracting the medium containing the target and probe moieties with an aliquot of dT_{10}-magnetic beads having 3 micrograms/ml of dA_{50} binding capacity following prehybridization procedures to reduce nonspecific binding to the magnetic bead. The magnetic bead and the probe-target complex was incubated at room temperature in 0.1 ml prehybridization buffer in 5 ml polypropylene tubes for two to five minutes.

The tubes were placed into a Corning tube magnetic separator. The Corning tube magnetic separator upon activation imposes a magnetic field through the polyproplyene tubes which immobilizes the magnetic beads on the inner walls of the tubes. During the time that the magnetic beads are immobilized on the side walls of the polypropylene tubes, the original medium was removed and discarded.

While immobilized, the beads were washed three times with 0.6 ml of prehybridization buffer containing isoamyl alcohol as a defoamant. Following the addition of the prehybridization buffer, the beads were resuspended by removing the tubes from the magnetic field and by subjecting the medium to vigorous vortexing.

Next, the magnetic field was reapplied to immobilize the beads allowing the prehybridization buffer to be removed and discarded. The cycle of adding the prehybridization buffer, resuspending the beads, immobilizing the beads, and discarding the prehybridization buffer was repeated twice. Target-probe complexes held on the beads are available for further processing including additional steps of detection, background capture or further cycles of target capture.

A preferred target capture procedure includes release of the target-probe complex and recapture on a second support. Preferably the support is chemically distinct from the first support.

Release of the target-probe complex is effected in the following typical protocol. After the removal of the last prehybridization buffer, prehybridization buffer was added to the tube containing the beads. The beads were incubated with agitation at 60° C. for one–two minutes to release the probe-target complexes from the bead. The magnetic separator was again activated with the temperature at 60° C. and the eluate, containing free target-probe complexes, is removed from the tube. The eluate can be recaptured on additional retrievable supports or subjected to final capture on conventional supports. It will be recognized by those skilled in the art that the capture and release of the target probe complex from retrievable supports such as the magnetic beads of the present example can be repeated as often as desired to reduce hybridization backgrounds.

Final capture of the probe-target complex was typically performed on nitrocellulose filters or nylon membranes containing nonspecifically bound or covalently bound dT-3000. Thus, the target-probe complexes carried upon the magnetic beads were released from the magnetic beads by heating the beads to 60° C. in prehybridization buffer for two minutes. The beads were immobilized and the eluate removed and passed through a 0.2 micron acrodisc (Gelman) to remove magnetic fines. The nitrocellulose filter containing dT-3000 selected, bound, and captured the dA tail on the unlabeled probes.

The use of a chemically different solid support for the final capture of the target-probe complex avoids binding background molecules which may have a high affinity for previously used supports. By way of illustration, it is possible for lower level contaminants with a natural high affinity for a particular support to repeatedly bind and elute with a support along with probe-target complexes. Such low level contaminants cannot be diluted out by repeated use of a retrievable support of the same composition as completely as by exposing them to supports of very different compositions. Low level contaminants can also be lowered by utilizing chemically distinct means to release the target-probe complexes from supports and recapture.

F. Background Capture Procedures

Background capture procedures permit the selective reduction of background noise permitting the detection of signal indicative of the presence of target. Background capture can be applied in a single probe system or in systems using more than two probes. For example, in background capture procedures featuring a single probe, the probe includes a label moiety and a ligand. The probe is capable of binding to a target and the ligand is capable of forming a stable bond to a support only when the probe is unbound to target.

Similarly, by way of example, background capture procedures featuring multiple probes in conjunction with target capture include two probes. A first target capture probe, having an unlabeled ligand capable of binding to a first support is used to capture the target and a second background capture probe, having a label moiety capable of detection includes a second ligand capable of binding to a second background support. Background capture is a valuable supplement to target capture for enhancing the signal to noise data of an assay.

The following sets forth a typical background capture protocol using a first target capture probe A532 and a second background capture probe A726 and a target enterotoxin gene elt A1. Those skilled in the art will recognize that the probes used for demonstration purposes are merely a matter of choice. Other probes could be used also.

The probe A532 was tailed with approximately 100 dA residues capable of reversibly binding to dT_{10} covalently linked magnetic beads for initial target capture and dT_{3000} nonspecifically bound to nitrocellulose for a final target capture. The probe A726 was end labeled with the random addition of approximately three residues of ^{32}P-dC and ^{32}P-dG to the 3' end with terminal transferase. The probe A726 is capable of binding to dC-cellulose when the probe is not hybridized to target.

A solution containing the target-first and second-probe-complex and potentially containing unbound second probe is mixed with dC-cellulose and the temperature of the mixture maintained at 37° C. The temperature, 37° C., is higher than the dissociation temperature of dG_7 with oligo dC, preventing binding of the target-first and second-probe-complex to the dC-cellulose. The temperature is also lower

than the dissociation temperature of dG_{10} with oligo dC to promote binding of unbound second probe having a dG tail to the dC-cellulose. Additional, the target-first and second probe complex is sterically hindered to a greater degree in its approach to the dC-cellulose support than unbound second probe. The dC-cellulose containing the second probe A726 is removed by centrifugation, however, those skilled in the art will appreciate that other methods such as filtration may be used as well. The remaining eluate contains target-first and second probe complexes and a reduced concentration of unbound labeled second probe A726.

G. EXAMPLES

Individual skilled in the art will recognize that the typical protocols for retrievable support preparation, probe preparation, target capture and background capture are capable of modification to suit special needs and purposes. The following examples incorporate the typical procedures outlined above unless otherwise noted.

Example 1

Target Capture and Assay Using Magnetic Bead

A target capture assay was performed with two probes and a magnetic bead retrievable support. The target included the Xba 1-Hind III fragment of the enterotoxigenic gene elt Al. A first probe included an A532 thirtimer oligonucleotide probe which was tailed with 130 unlabeled dA residues capable fo binding to the dT_{10} residues of the magnetic beads support. A second probe included an A483 thirtimer oligonucleotide probe capable of binding to the same target 20 nucleotides downstream from the site of hybridization of the first probe. The second probe was labeled by tailing the thirtimer oligonucleotide with ^{32}P-dCTP and ^{32}P-dGTP to a specific radioacitivity of 10^{10} DPM/microgram.

The tailed first probe and the labeled second probe were incubated at 65° C. for 15 minutes in 1.4M sodium chloride with various quantities of heat denatured 475 mer restriction fragments of the tox gene. As a nonspecific binding background control, the tailed first probe and labeled second probe were incubated in identical solutions in the absence of any target. As specific binding controls, two additional reaction mixtures were formed. One reaction mixture included the tailed first probe and the unlabeled second probe incubated with four micrograms of denatured *E. coli* DNA, and a second reaction mixture of the tailed first probe and the labeled second probe incubated in ten micrograms of denatured human DNA in identical reaction mixtures without any target DNA.

After a 15 minute hybridization period, the samples were incubated for five minutes with dT-derivatized magnetic beads in 0.7 milliliters of 0.75 molar phosphate buffer (pH 6.8). The beads were magnetically immobilized and washed extensively as described previously. The target-probe complex was eluted from the beads at 60° C. in 0.6 milliliters of 0.20 molar phosphate buffer (pH 6.8). The first set of beads was separated from the eluate and the target probe complex. A second group of magnetic beads was added to the eluate and brought to binding conditions to capture the target and probe complex again. The second set of beads was washed and the target again eluted from the beads and the beads separated from the eluate.

A third set of beads was added to the eluate containing the target-probe complex and placed under binding conditions to allow the beads to once again capture the target-probe complex. The beads were then washed extensively and the target eluted from the beads as previously described. The beads were then separated from the eluate and the eluate

passed through dT_{3000}-nylon into two millimeter square slots, capturing the target-probe complex.

The dT_{3000} nylon membrane was prepared in which 2 μg dT_{3000} was covalently bound to nylon using a hybri-slot apparatus (Betlesda Research Laboratory). Briefly, dT_{3000} (Life Sciences) was dotted directly onto a nylon membrane such as Gene-Screen™ (New England Nuclear) in a salt-free Tris buffer. The membrane was dried at room temperature for 10 minutes, and then dried under an infrared lamp for an additional 10 minutes before cooling back to room temperature for another 10 minutes. The filter apparatus containing the nylon membrane was inverted on a uv-transilluminator (Fotodyne) and exposed to uv light for two minutes at 40 uW/cm^2 to cross-link the dT_{3000} to the filter.

The dT_{3000} membrane was prehybridized by sequentially passing the following solutions through the membrane:

(1) 1% SDS;

(2) 0.5 mg/ml BSA in 0.5% SDS; and, finally,

(3) prehybridization buffer

The dT_{3000}-nylon potentially containing the target-probe complex was washed with 0.2 molar sodium phosphate and 5 millimolar EDTA. The nylon support was monitored overnight by audioradiography for the presence of the ^{32}P label moieties of the second probe. Following audioradiography, the bands were cut out of the filter and counted in base scintillation fluid. The counts were 2100 and 1400 counts per minute in the solution containing three femtomoles (10^{-15} moles) of a restriction fragment containing the tox gene. Samples containing 30 attomoles (10^{-18} moles) of the restriction fragment containing the tox gene produced a count of 62 counts per minute.

A third sample containing no DNA produced seven counts per minute. A fourth sample containing ten micrograms of heat denatured human DNA produced 0 counts per minute. A fifth solution containing 4 micrograms of heat denatured *E. coli* DNA produced 7 counts per minute. The absolute sensitivity of the protocol was estimated to be 10^{-18} of tox gene. The overall efficiency of the recovery of labeled target-probe complex was estimated to be 1 to 2 percent of the input. The assay demonstrated good specificity. There is no more labeled probe in the samples containing human DNA or *E. coli* DNA than in the sample containing no DNA at all. Repetition of the experimental protocol has produced overall efficiency of capture of the target of almost 5 percent. The procedures reduced background from an initial level of 10^{11} molecules of the labeled unhybridized probes to about 10^4 moles. The reduction and background represents a 7 log improvement which more than adequately compensates for the reduction and efficiency of capture.

Example 2

The present example features target capture with background capture. Target and background capture was effected using an unlabeled first target capture probe, A532 as described in target capture, and a second labeled background capture probe A726.

First, 160 ng/ml dA-tailed A532 and 40 ng/ml ^{32}P-labeled probe A726 were combined to form a probe mix. The probe mix was added to 5 μl of bacterial extract containing various amounts of enterotoxigenic gene. The extract-probe mix was incubated at 22° C. for 15 minutes.

After a fifteen minute hybridization period, the samples were diluted with ten volumes of prehybridization buffer incubated for five minutes with dT-derived magnetic beads in 0.7 ml of 0.75M phosphate buffer (pH 6.8) to effect target capture. The beads were magnetically immobilized and washed extensively. The target-first and second probe com-

plex was eluted from the first support as previously described and the first solid support removed.

Next, the eluate containing the target-first and second-probe-complex and potentially containing unbound second probe was mixed with dC-cellulose and the temperature of the mixture maintained at 37° C. The temperature 37° C. is higher than the dissociation temperature of dG_7 with oligo dC to prevent binding of the target-first and second-probe-complex to the dC-cellulose. The temperature was also maintained lower than the dissociation temperature of dG_{10} with oligo dC to promote binding of unbound second probe having a dG_{10} tail to the dC-cellulose. The target-first and second probe complex is sterically hindered to a greater degree in its approach to the dC-cellulose support than unbound second probe. The dC-cellulose was removed by centrifugation, however, those skilled in the art will appreciate that other methods such as filtration may be used as well.

The remaining eluate was passed through a 0.2 micron acrodisc (Gelman) to remove magnetic and cellulose fines. Then, the eluate was passed through nitrocellulose filters containing dT_{3000} at 22° C. The nitrocellulose effected final target capture.

Table 2 sets forth below the application of background capture:

TABLE 2

Step	Signal (CPM)	Noise (CPM)
First Experiment		
Before Target Capture	(unknown)	200,000
After Target Capture	1058	231
After Background Capture	495	25
After Filtration	395	<1
Second Experiment		
Before Target Capture	(unknown)	400,000
After Target Capture	1588	642
After Background Capture	1084	69
(Filtration step was not performed)		

The removal of noise to less than 1 cpm allows the detection of very small quantities of target within a sample. As little as 10^{-18} moles of target have been detected which is within the range necessary for clinical applications.

One round of target capture removed about 3 logs of background. One round of background capture removed 1 log of background not already removed by the primary target capture. Final target capture by filtration (a second round of target capture) removed 2 logs of background not removed by either of the first two steps. Target and background capture methods work independently to reduce backgrounds by about 6 logs in this example. Background capture appears to work better when applied after a first target capture. Apparently, background capture is much more sensitive to impurities in the sample than target capture.

The combination of background capture following target capture produces a greater benefit than either applied alone.

Although the foregoing examples recite radioactive label moieties, it is expected that the present procedure would have its greatest impact on assay procedures utilizing non-radioactive label moieties. In particular, the present invention would be applicable to luminescent label moieties including fluorescent and chemiluminescent agents. Suitable fluorescent labels include, by way example without limitation, fluoroscein, pyrene, acridine, sulforhodamine,

eosin, erythrosin, and derivatives thereof. Suitable chemiluminescent agents include, by way of example without limitation, microperoxidase, luminol, isoluminol, glucose oxidase, acridinium esters and derivatives thereof.

Example 3

The following example features nonradioactive label moieties and multiple rounds of target capture from spiked biological media. The spiked biological media resembles samples which would be obtained clinically in a medical setting.

Cell extracts of enterotoxigenic *E. coli* and wild type *E. coli* were prepared as previously described. To measure the sensitivity of the detection of tox genes in an environment analogous to a clinical setting, extract containing toxigenic bacteria was diluted with the extract containing the wild type *E. coli* as previously described.

The following materials were obtained from anonymous donors: human stool sample, cow's milk, human saliva, human phlegm, human whole blood, human serum, human urine and human semen. Clinical-type samples were solubilized over a time period of ten minutes. The stool sample, due to its solid nature, was solubilized in a solution of 5M GuSCN, 0.3M Tris-HCl (pH 7.4), 0.1M EDTA (pH 7), 1% betamercaptoethanol. Following solubilization, aliquots of the sample were made and each aliquot was spiked with a known quantity of either toxigenic *E. coli* or wild type *E. coli*. The mixture was then passed through a crude filtration (Biorad Econocolumn) and heated to 100° C. for five minutes.

The remainder of the samples were more liquid in nature and were handled differently than stool. Liquid samples were added to solid GuSCN to make the final concentration 5M. The solid GuSCN also contained sufficient Tris-HCl, EDTA, and betamercaptoethanol to make the final concentrations the same as in the stool example. Next, aliquots of the samples were made and each aliquot was spiked with a known amount of toxigenic *E. coli* or wild type *E. coli*. The mixture was passed through a crude filtration (Biorad Econocolumn and heated to 100° C. for five minutes.

The preparation of probes in Example 3 differs from previous examples. A first capture probe was generated with the plasmid pBR322. The plasmid was restricted with Hha I and Hae III and plasmid fragments were tailed with about 100 dA residues with terminal transferase. The target plasmid contains extensive homology with pBR322 (Spicer and Noble, *J. Biol.* 257: 5716–21). Thus, first capture probes were generated from multiple fragments of both strands of the plasmid pBR322 in relatively large quantities.

A second label probe was made to combine specifically to the target enterotoxin gene. The second label probe was generated from an EcoRI-Hind III restriction fragment of the elt Al gene cloned into bacteriophage M13mp18. The *E. coli* HB101 was infected with the bacteriophage and grown to midlog phase. The *E. coli* were harvested, and the bacteriophage were isolated. Bacteriophage was nick-translated with biotinylated dCTP (Enzo-Biochemicals) using a stock nick-translation kit available from Bethesda Research Laboratories. Approximately five percent of the nucleotides were replaced with biotinyl nucleotides to form a biotin-labeled second probe.

A probe mix was made by combining 8 μg/ml of the second M13-tox probe with 4 μg/ml of the first dA-tailed first probe in 20 mM Tris-HCl (pH 7.4) and 2 mM EDTA. The probe mix was heated to 100° C. for ten minutes to denature the probes.

One volume of the probe mix was mixed with one volume of sample of the dilution series to form a hybridization mixture. The hybridization mixture was maintained under hybridization conditions at 57° C. for fifteen minutes. The hybridization mixtures were subsequently diluted with ten volumes of blocking buffer 0.75M sodium phosphate, pH 6.8, 0.5% sodium lauryl sarcosine, 10 mg/ml *E. coli* DNA, 0.5 mg/ml bovine serum albumin (BSA-nuclease free) and 5 mM EDTA). To the hybridization mixture were added dT_{10} derivized magnetic beads prepared as previously described. Hydridization conditions were maintained approximately one minute at 22° C. The beads were then separated from the hybridization mixture by magnetically immobilizing the beads. The beads were washed twice during a fifteen minute time interval to remove impurities in the biological specimen and unhybridized biotin labeled second probe.

Next, in a time period of approximately one minute, the first and second probe-target complex was eluated from the magnetic beads at 65° C. in blocking buffer. The eluate and the first beads were separated.

In a time period of approximately seven minutes, the first and second probe-target complex was releasibly bound to a second set of beads and again released. A second set of dT_{10} derivized beads were then added to the eluate and hybridization conditions maintained for approximately one minute at 22° C. The beads were then washed and resuspended in blocking buffer. The bead blocking buffer mixture was then brought to 65° C. to release the first and second probe-target complex.

Over a time period of five minutes, final capture of the first and second probe-target complex on nitrocellulose was effected. The eluate from the second beads was filtered through a Gelman acrodisc (0.2 micron). The eluate containing the first and second probe-target complex was then passed through a dT_{3000} nitrocellulose filter (prehybridized with blocking buffer) at 22° C.

In a time period of approximately thirty minutes the filter was further processed to detect the biotin labels of the second probe. Buffer compositions used in detection are identified below in Table 3.

TABLE 3

Detection Buffers

Buffer Number	Composition
1	1 M NaCl, 0.1 M Tris-HCl (pH 7.4), 5 mM $MgCl_2$, 0.1% Tween-20
1a	No. 1 with 5 mg/ml BSA, 10 micrograms/ml *E. coli* DNA
2	No. 1 with 5% BSA, 0.5% Tween-20
3	0.1 M NaCl, 0.1 M Tris-HCl (pH 9.5), 50 mM $MgCl_2$

First, the filter carrying the first and second probe-target complex, was incubated for approximately five minutes in detection buffer No. 2. Next, the filter was incubated for five minutes in a 1:200 dilution of strepavidin-alkaline phosphatase (Bethesda Research Laboratories) in detection buffer No. 1a. Thereafter, the filter was washed three times in one minute in detection buffer No. 1 and then washed twice in one minute in detection buffer No. 3.

Next, 5-Bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium (NBT) (Kierkegaard and Perry) were diluted twelve times in detection buffer No. 3, and filtered through a 0.2 micron acrodisc. The diluted BCIP and NBT

solution was added to the filter and color allowed to develop for fifteen minutes at 37° C.

Next, the filter was incubated in 50 mM Tris-HCl (pH 7.4) and 10 mM EDTA for one minute to stop the reaction. Sensitivity was determined visually on the filter or by densitometric scanning on a CS 930 (Shimadzu Scientific).

The steps in the present method are outlined below in Table 4.

TABLE 4

	Elapsed Time	
Step Number	Time Required (min.)	Cumulative Timed (min.)
1. Dissolution of biological sample; denaturation of DNA	10	10
2. Add labeled and unlabeled probes; hybridize in solution at 57° C.	15	25
3. Capture probe-target complex on magnetic beads	1	26
4. Wash magnetic beads to remove impurities in the biological specimen and hybridization backgrounds	15	41
5. Elute the probe-target complex	1	42
6. Repeat steps 3–5 on a second set of beads (except abbreviate the washes)	7	49
7. Bind the probe-target complex to dT_{3000}-nitrocellulose	5	54
8. Incubate filter in blocking buffer	5	59
9. Bind streptavidin-alkaline phosphatase	5	64
10. Wash	5	69
11. Add dyes to detect enzyme	15	84
12. Quench reaction	1	85

Although Table 4 set forth an example wherein the elapsed time is just over one hour, the procedure is capable of modification and can be performed in shorter times. Nonradioactive probe assays of comparable sensitivity may require twelve hours to several days and require extensive sample preparation.

The sensitivity of the present assay is set forth in Table 5 below:

TABLE 5

	Sensitivity Level	
Biological Specimen	Concentration in the Hybridization Mixture	Number of Bacteria
bacterial extract alone		1500
human stool	2.5% (w/v)	2000
cow's milk	12.5% (v/v)	3000
human saliva	12.5% (v/v)	3000
human urine	12.5% (v/v)	9000
human semen	2.5% (v/v)	9000
human blood	12.5% (v/v)	9000
human serum	12.5% (v/v)	9000
human phlegm	12.5% (v/v)	9000

Further, the present procedures are capable of further modifications to improve sensitivities. For example, a combination of thermal elution and chemical elution in multiple captured release cycles produces a signal to noise ratio five times better than single forms of elution, either multiple thermal elutions alone or multiple chemical elutions alone.

Applying the same releasing or elution procedure tends to release the same background from the support. However,

applying different releasing conditions tends to retain background on the support that would otherwise be eluted. It is unlikely that background will behave identically to target under two physically or chemically distinct conditions.

A typical chemical elution of target-probe complexes on magnetic beads includes bringing beads in contact with 3 M GuSCN for one minute at room temperature. Examples of thermal elutions have been described previously.

The ability to detect bacteria would also be improved by directing probes to ribosomal RNA sequences. Ribosomal RNA sequences present to thousand fold increase in target per cell as compared to genomic DNA and clinically significant plasmid DNA.

The sensitivity of the above DNA or RNA target capture methods can be enhanced by amplifying the captured nucleic acids. This can be achieved by non-specific replication using standard enzymes (polymerases and/or transcriptases). After replication, the amplified nucleic acid can be reacted as above with capture probe, reporter probe, and capture beads to purify and then detect the amplified sequences.

In addition, where amplification is employed following purification of the target nucleic acids as described above, the amplified nucleic acids can be detected according to other, conventional methods not employing the capture probe, reporter probe, and capture beads described above, i.e., detection can be carried out in solution or on a support as in standard detection techniques.

Amplification of the target nucleic acid sequences, because it follows purification of the target sequences, can employ non-specific enzymes or primers (i.e., enzymes or primers which are capable of causing the replication of virtually any nucleic acid sequence). Although any background, non-target, nucleic acids are replicated along with target, this is not a problem because most of the background nucleic acids have been removed in the course of the capture process. Thus no specially tailored primers are needed for each test, and the same standard amplification reagents can be used, regardless of the targets.

The following are examples of the method.

Example 4

The following example illustrates the use of RNA polymerase to amplify target DNA captured by a method which is a variation of the capture method discussed above.

Referring to FIG. 4, target DNA of a sample is first reduced in size by shearing or by limited nuclease digestion, according to standard methods. A recA protein coated capture probe is then added to the digested target DNA (*Proc. Natl. Acid. Sci.* U.S.A. (1986) 83:9591) The recA protein coated probe contains a nucleic acid sequence (a) that is homologous to a first target (a^1) sequence of the target DNA, as well as a homopolymer sequence homologous to a nucleic acid sequence on a capture bead. This capture bead is then added to the mixture to isolate and purify the target nucleic acid, as described above.

The capture DNA is amplified by treatment of the mixture with *E. coli* RNA polymerase lacking sigma subunit, i.e., core enzyme; *E. coli* RNA polymerase is described by R. Burgess in *RNA Polymerase*, Cold Spring harbor press, pp. 69–100, and can be purchased from New England Biolabs, Beverly, Mass. The sigma subunit is removed according to the procedure described in J. Biol. Chem. (1969) 244:2169 and Nature (1969) =221=:43. Other phage or bacterial RNA polymerases that lack transcriptional specificity can also be

used. Core enzyme is added together with nucleotide triphosphates and a low salt transcription buffer such as described in Eur. J. Biochem. (1976) 65:387 and Eur. J. Biochem (1977) 74. 1107.

A suitable nucleotide triphosphate/transcription buffer solution has the following composition:

0 to 50 mM NaCl or KCl

25 mM Tris HCl pH 7.9 buffer

10 mM $MgCl_2$

0.1 mM EDTA

0.1 mM dithiothreital

0.5 mg/ml BSA

0.15 mM UTP. GTP. CTP. ATP

The resulting non-specific transcription of the target DNA produces many RNA transcripts of the target DNA which are then captured using a capture probe containing a sequence (b^1) homologous to a sequence (b) of the RNA transcripts. A reporter probe containing a sequence (c^1) homologous to another sequence (c) of the RNA transcript is then used for detection.

Example 5

In this example both non-specific replication of target DNA and transcription of that DNA are used to amplify capture target DNA.

Referring to FIG. 5, denatured sample DNA is captured as described above and the enzyme DNA polymerase (for example, Klenow fragment; Dur. J. Biochem, (1974) 45:623 available from New England Biolabs), random oligohexamer primers (i.e., Hexamers prepared to contain randomly selected bases at each nucleotide position in the hexamer) and deoxynucleotide triphosphates are added in appropriate buffers to cause replication of target DNA to form additional double stranded DNA. Suitable oligohexamer primers are available under catalog No. 27-2166 from Pharmacia, Inc. Piscotaway, N.J. A suitable deoxynucleotide triphosphate/ buffer solution has the following composition:

66 mM glycine-NaOH buffer, pH 9.2

6 mM $MgCl_2$

1 mM 1-mercaptoethonal

30 mM each d CTP, d GTP, d TTP. d ATP

Because the primers are random, some will, simple as a matter of statistics, bind to and cause replication of sample sequences, no matter what those sequences are. (Alternatively, the double stranded DNA can be formed by synthesis starting from capture probe a.) RNA polymerase lacking sigma subunit is then added along with nucleotide triphosphates and low salt transcription buffer. Transcription from the target DNA (which has been increase d in number) produces many RNA copies of this DNA. The RNA transcripts are then captured and detected as in example 4.

Example 6

In this example target DNA is replicated using DNA polymerase.

Referring to FIG. 5, sample DNA is denatured, reduced in size and captured as described in examples 4 and 5. DNA polymerase, for example, Klenow fragment, and deoxynucleotide triphosphates are added in appropriate buffer with random hexamer oligonucleotides to bring about non-specific double-stranded DNA syntheses. The in vitro synthesized DNA product is then made single stranded by heat treatment (e.g., 100° C. for three minutes), or its equivalent, and additional DNA polymerase is then added to replace that

rendered inactive by the heat treatment. Further in vitro DNA replication then is allowed to occur. The heat treatment and polymerization reactions are repeated about 10 times to produce an approximately 1,000-fold increase in the level of target DNA. The replicated DNA is denatured in vitro using heat or alkali and then captured and detected as described previously.

Example 7

In this example, rRNA or RNA transcribed from target DNA is purified using a capture probe, described above. The hybrid duplex is then denatured and single stranded nucleic acids are then replicated non-specifically using Qβ replicase (methods in Enzymology (1979) 60:628. This replicase replicated both messenger RNA and ribosomal RNA non-specifically under the conditions described by Blumental, Proc. Natl. Acad. Sci. U.S.A. 77:2601, 1908. Because the replication product is a template for the enzyme, the RNA is replicated exponentially.

While preferred embodiments have been illustrated and described, it is understood that the present invention is capable of variation and modification and, therefore, should not be limited to the precise details set forth, but should include such changes and alterations that fall within the purview of the following claims.

We claim:

1. A method for amplifying a target polynucleotide contained in a sample comprising the steps of:

(a) contacting the sample with a first support which binds to the target polynucleotide;

(b) substantially separating the support and bound target polynucleotide from the sample; and

(c) amplifying the target polynucleotide.

2. The method of claim 1 wherein the first support is retrievable.

3. The method of claim 1 wherein the first support includes a probe which binds with the target polynucleotide.

4. The method of claim 1 wherein the target polynucleotide is amplified with a polymerase.

5. The method of claim 4 wherein the polymerase is a DNA polymerase, an RNA polymerase, a transcriptase or Qβ replicase.

6. The method of claim 4 wherein the target polynucleotide is a DNA polynucleotide and the polymerase is a DNA polymerase.

7. A method for detecting a target polynucleotide contained in a sample comprising the steps of:

(a) contacting the sample with a first support which binds to the target polynucleotide;

(b) substantially separating the first support and bound target polynucleotide from the sample;

(c) amplifying the target polynucleotide; and

(d) detecting the presence of the amplified target polynucleotide.

8. The method of claim 7 wherein the first support is retrievable.

9. The method of claim 8 wherein the first support includes a probe which binds with the target polynucleotide.

10. The method of claim 7 wherein the target polynucleotide is amplified with a polymerase.

11. The method of claim 10 wherein the polymerase is a DNA polymerase, an RNA polymerase, a transcriptase or Qβ replicase.

12. The method of claim 11 wherein the target polynucleotide is a DNA polynucleotide and the polymerase is a DNA polymerase.

13. The method of claim 7 wherein the amplified target polynucleotide is contacted with a label.

14. The method of claim 7 wherein the amplified target polynucleotide is contacted with a labeled probe.

15. The method of claim 7 wherein the amplified target polynucleotide is contacted with a second support which binds to the amplified target polynucleotide.

16. The method of claim 15 wherein the amplified target polynucleotide is contacted with a labeled probe.

17. The method of claim 16 wherein the target polynucleotide is amplified with a polymerase.

18. The method of claim 17 wherein the target polynucleotide is a DNA polynucleotide and the polymerase is a DNA polymerase.

19. A method for detecting a target polynucleotide contained in a sample comprising the steps of:

(a) contacting the sample with a first support which binds to the target polynucleotide;

(b) substantially separating the first support and bound target polynucleotide from the sample;

(c) amplifying the sample with a DNA polymerase;

(d) contacting the amplified target polynucleotide with a second support which binds to the amplified target polynucleotide and also with a labeled probe which binds to the amplified target polynucletide; and

(e) detecting the presence of the amplified target polynucleotide.

20. A kit for detecting a target polynucleotide contained in a sample comprising:

(a) means for substantially separating the target polynucleotide from the sample;

(b) means for amplifying the target polynucleotide;

(c) means for binding the amplified target polynucleotide to a solid support; and

(d) means for labeling the amplified target polynucleotide.

21. The kit of claim 20 wherein:

(a) the means for substantially separating the target polynucleotide from the sample include a first support;

(b) the means for amplifying the target polynucleotide include a polymerase;

(c) the means for binding that amplified target polynucleotide to a solid support include a capture probe which binds to the solid support and to the amplified target polynucleotide; and

(d) a detector probe for labeling the amplified target polynucleotide.

22. The kit of claim 21 further comprising a capture probe which binds to the first support and to the target.

23. The kit of claim 22 wherein the polymerase is a DNA polymerase and the detector probe is labeled.

24. A kit for amplifying a target polynucleotide contained in a sample comprising:

(a) means for substantially separating the target polynucleotide from the sample and

(b) means for amplifying the target polynucleotide.

25. The kit of claim 24 wherein:

(a) the means for substantially separating the target polynucleotide from the sample includes a support which binds to the target polynucleotide and

(b) the means for amplifying the target polynucleotide includes a polymerase.

26. The kit of claim 25 wherein:

(a) the polymerase is a DNA polymerase; and

(b) the means for substantially separating the target polynucleotide from the sample includes a probe which binds to the target polynucleotide and the support.

27. A method for amplifying a target polynucleotide contained in a sample medium comprising the steps of:
(a) contacting the sample medium with reagent comprising a first nucleic acid probe which binds to the target to form a probe-target complex;
(b) contacting the sample medium with a support which binds to the first nucleic acid probe of the probe-target complex;
(c) substantially separating the support and bound probe-target complex from the sample medium:
(d) contacting the support and bound probe-target complex with a second medium;
(e) releasing the probe-target complex into the second medium;
(f) substantially separating the support from the second medium; and
(g) amplifying the target polynucleotide.

28. A method for detecting a target polynucleotide contained in a sample medium comprising the steps of:
(a) contacting the sample medium with reagent comprising a first nucleic acid probe which binds to the target to form a probe-target complex;
(b) contacting the sample medium with a support which binds to the first nucleic acid probe of the probe-target complex;
(c) substantially separating the support and bound probe-target complex from the sample medium;
(d) contacting the support and bound probe-target complex with a second medium;
(e) releasing the probe-target complex into the second medium;
(f) substantially separating the support from the second medium;
(g) amplifying the target polynucleotide; and
(h) detecting the presence of the target polynucleotide.

29. The method of detecting a target polynucleotide of claim 28 wherein the target polynucleotide is amplified with a polymerase.

30. The method for detecting a target polynucleotide of claim 29 wherein the polymerase is a DNA polymerase, an RNA polymerase, a transcriptase, or Qβ replicase.

31. The method for detecting a target polynucleotide of claim 30 wherein the polymerase is a DNA polymerase.

32. The method for amplifying a target polynucleotide of claim 27 wherein the target polynucleotide is amplified with a polymerase.

33. The method for amplifying a target polynucleotide of claim 32 wherein the polymerase is a DNA polymerase.

34. A method for amplifying a target polynucleotide contained in a sample medium comprising the steps of:
(a) contacting the sample medium with a support and a probe which binds to the target polynucleotide and the support;
(b) substantially separating the support and bound probe and target polynucleotide from the sample medium;
(c) contacting the support and bound probe and target polynucleotide with a second medium;
(d) releasing the target polynucleotide into the second medium;
(e) substantially separating the support and bound probe from the second medium; and
(f) amplifying the target polynucleotide.

35. The method for amplifying a target polynucleotide of claim 34 wherein the target polynucleotide is amplified a polymerase.

36. The method for amplifying a target polynucleotide of claim 35 wherein the polymerase is a DNA polymerase, an RNA polymerase, a transcriptase or Qβ replicase.

37. The method for amplifying a target polynucleotide of claim 36 wherein the polymerase is a DNA polymerase.

38. A method for detecting a target polynucleotide contained in a sample medium comprising the steps of:

(a) contacting the sample medium with a support and probe which binds to the target polynucleotide and the support;

(b) substantially separating the support and bound probe and target polynucleotide from the sample medium;

(c) contacting the support and bound probe and target polynucleotide with a second medium;

US005200314A

(d) releasing the target polynucleotide into the second medium;

(e) substantially separating the support and bound probe form the second medium;

(f) amplifying the target polynucleotide; and

(g) detecting the presence of the amplified target polynucleotide.

39. The method for detecting a target polynucleotide of claim **38** wherein the target polynucleotide is amplified with a polymerase.

40. The method for detecting a target polynucleotide of claim **39** wherein the polymerase is a DNA polymerase.

* * * * *

US005538848

FIG. Ia



0053600-0000000

FIG. 1b


TARGET
PROBE
TARGET
SMALL AMT OF
DNA
RNA
CELLULAR DEBRIS
IMPURITIES
NONSPECIFICALLY
BOUND
TO SUPPORT
PROBE
TARGET
TARGET
STEP 5
DENATURATION
TARGET
TARGET
PROBE
SUPPORT
DNA
RNA
CELLULAR
DEBRIS
IMPURITIES
NONSPECIFICALLY
BOUND
TO SUPPORT
OR NOW IN
SOLUTION
TARGET
TARGET
STEP 6
SEPARATION OF OLD SUPPORT
FROM SECOND MEDIUM AND
INTRODUCTION OF NEW SUPPORT
UNDER BINDING CONDITIONS
TARGET
TARGET
PROBE
SUPPORT
PROBE
A LESSER
AMOUNT OF
DNA
RNA
CELLULAR
DEBRIS
IMPURITIES
PREVIOUSLY
NONSPECIFICALLY
BOUND TO SUPPORT AND
DISSOLVED IN TO SECOND
MEDIUM AND AGAIN
NONSPECIFICALLY
BOUND TO SUPPORT
TARGET
STEP 7
REPEAT CYCLE AS NECESSARY
STEP 8
DETECT TARGET

FIG. 2a



0353808

FIG. 2b


TARGET
A_1
L_1
S_1
A_1
A_1
L_1
P_1
SEPARATE RETRIEVABLE SUPPORT FROM TARGET-PROBE COMPLEX BY DENATURATION
MONITOR SAMPLE FOR LABEL
STEP 5
TARGET
P_1
P_2
L_1
L_2
P_1
L_1
A_1
A_1
S_1
A_1
A_1
STEP 6
REMOVE RETRIEVABLE SUPPORT
TARGET
P_1
L_1
A_1
S_2
A_1
A_1
L_1
P_1
STEP 7
TARGET
P_1
L_1
P_2
L_2
DETECT
REPEAT CYCLE
MONITOR SAMPLE FOR LABEL
STEP 8

FIG. 3



0353906 - 030800

FIG.4


TARGET DNA IN ROUGH SAMPLE
STEP 1
CAPTURE PROBE (REC A PROTEIN COATED)
CAPTURE BEAD
BINDING CONDITIONS
BEAD
A
C'
B'
A'
COMPLEMENTARY HOMOPOLYMER TAILS
STEP 2
ISOLATE BEADS
TARGET DNA (SUBSTANTIALLY FREE OF SAMPLE IMPURITIES, DEBRI, EXTRANEOUS POLYNUCLEOTIDES
STEP 3
CORE RNA POLYMERASE
LOW SALT BUFFER
TARGET DNA
C'
B'
A'
RNA COMPLEMENTARY TO TARGET DNA
C
B
A
N
STEP 4
LABEL PROBE
CAPTURE PROBE
CAPTURE SUPPORT
LABEL PROBE
CAPTURE PROBE
*
COMPLEMENTARY HOMOPOLYMER TAILS
C
B
A
AMPLIFICATION PRODUCT
SUPPORT

FIG. 5


TARGET DNA IN ROUGH SAMPLE
CAPTURE PROBE
CAPTURE BEAD
STEP 1
A
BEAD
C'
B'
A'
COMPLEMENTARY
HOMOPOLYMER TAILS
STEP 2
ISOLATE BEADS
TARGET DNA (SUBSTANTIALLY FREE OF
SAMPLE IMPURITIES, DEBRI,
EXTRANEOUS POLYNUCLEOTIDES)
STEP 3a
DNA POLYMERASE
HEXAMER PRIMERS
C'
B'
A'
C
B
A
STEP 3b
CORE RNA POLYMERASE
LOW SALT BUFFER
DNA
RNA
N
STEP4
LABELLED PROBE
CAPTURE PROBE
SUPPORT
AMPLIFICATION TARGET
CAPTURE
PROBE
SUPPORT
LABEL
PROBE
TARGET/AMPLIFICATION
PRODUCT
CAPTURE
PROBE

FIG. 6


TARGET DNA IN ROUGH SAMPLE
STEP 1
CAPTURE PROBE
CAPTURE BEAD
CAPTURE PROBE
A
BEAD
TARGET
C' B' A'
COMPLEMENTARY HOMOPOLYMER TAILS
STEP 2
ISOLATE BEAD
TARGET DNA (SUBSTANTIALLY FREE OF SAMPLE IMPURITIES, DEBRI, AND EXTRANEOUS POLYNUCLEOTIDES)
STEP 3a
DNA POLYMERASE
HEXAMER PRIMERS
C B A
C' B' A'
FIRST COMPLEMENT TARGET
STEP 3b
1. DENATURE
2. DNA POLYMERASE
SECOND COMPLEMENT
TARGET
FIRST COMPLEMENT
COMPLEMENT TO FIRST
STEP 4
DENATURE
LABEL PROBE
CAPTURE SUPPORT
CAPTURE PROBE
TARGET/AMPLIFICATION PRODUCT
SUPPORT
LABEL PROBE
CAPTURE PROBE
COMPLEMENTARY HOMOPOLYMER TAILS
AMPLIFICATION PRODUCT

FIG. 7


SAMPLE
SOLUBILIZING AGENTS
REAGENT
FIRST SUPPORT
REACTION VESSEL
CONVEYING MEANS
AGITATION ELEMENT
HEATER ELEMENT
AGITATION ELEMENT
STATION 1
STATION 2
STATION 3
WASH
SAMPLE MEDIA
SECOND SUPPORT
FIRST SUPPORT
COOLING ELEMENT
MAGNETIC ELEMENT
HEATING ELEMENT
STATION 4
STATION 5
STATION 6
SECOND MEDIA
STATION 7
STATION 8
STATION 9
DETECTOR
STATION 10



FIG. 8

VYSIS, INC.–US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Atty.	Status	Applin. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

0953905 . 030800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

USA	25,835.11-US	CON	NBG	PROSECUTN	08/238,080	5/3/94				TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS	COLLINSM L	AC

Redacted

095339065 . 030600

VYSIS, INC.–US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

09533906 . 030800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

09533906.030800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

09533906 .030606

VYSIS, INC.–US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

0953939D6 .030830D

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

0963939065.020800

SCHEDULE 1

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

095339005 .030800

VYSIS, INC.–US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

09533905 .030800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

09533906 .030696

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

0953939306 . 030800

VYSIS, INC.–US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

0963939061.030800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

D953390S .. D390800

VYSIS, INC.–US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

0563906 .030800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

0953390B6 .030B800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

09533906 .030800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Appln. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

09533906 .030800

VYSIS, INC.--US and FOREIGN PATENTS/APPLICATIONS

Country	Docket #	Type	Attny.	Status	Applin. #	Filing Date	Patent #	Issue Date	Expire Date	TITLE	1st Inventor	Assignee

Redacted

09533906 .030396

PATENT
Attorney Docket No. 1147-0142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of: U.S. Patent No. 5,750,338	)	
Mark L. Collins et al.	)	Group Art Unit: Unassigned
Reissue Serial No.: Unassigned	)	Examiner: Unassigned
Reissue Application Filed: Herewith	)	
For: TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS	)	

BOX REISSUE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

REISSUE DECLARATION UNDER 37 C.F.R. § § 1.172 and 1.175

As a duly authorized representative of the assignee of the entire interest in this patent, I, Norval B. Galloway, do hereby state and declare as follows:

1. I am the Patent Counsel of Vysis, Inc., the Assignee of the entire right, title, and interest in U.S. Patent No. 5,750,338 by virtue of an assignment from the inventors to Amoco Corporation in a predecessor application (U.S. Serial No. 07/136,920), recorded at Reel 4843, Frame 0373, and by virtue of a subsequent Assignment of Patents and Applications from Amoco Corporation to Vysis Inc (copy attached to the Consent of Assignee, Offer to Surrender Original Patent, And Statement Under 37 C.F.R. § 3.73(b), filed herewith). Accordingly, I am empowered to sign this paper on behalf of the Assignee.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

2. I believe that Mark L. Collins, Donald N. Halbert, Walter King, and Jonathan M. Lawrie are the original joint inventors of the subject matter which is described and claimed in United States Patent No. 5,750,338, granted on May 12, 1998, and for which a reissue patent is sought on the invention entitled "Target and Background Capture Methods with Amplification for Affinity Assays."

3. I have reviewed and understand the contents of the above-identified specification, including the original patent claims, and the claims in the Preliminary Amendment filed herewith. I also believe that the claims in the Preliminary Amendment do not enlarge the scope of the claims of the original patent.

4. I acknowledge the duty to disclose information that is material to patentability and to the examination of this reissue application in accordance with 37 C.F.R. § 1.56.

5. I believe that U.S. Patent No. 5,750,338 is partially inoperative because, without any deceptive intention, the inventors claimed less than they had the right to claim in the patent.

6. An error which is a statutory basis for reissue is that the patent fails to contain claims of intermediate scope. *See* Hewlett-Packard Co. v. Bausch & Lomb, Inc., 882 F.2d 1556, 1564-1565, 11 U.S.P.Q.2d 1750, 1757 (Fed. Cir. 1989); *In re Handel* 312 F.2d 943, 945- 46 n.2, 136 U.S.P.Q. 460, 462 n.2 (C.C.P.A. 1963). The Assignee is filing this reissue application to introduce intermediate scope claims.

7. The above-described error and all other errors corrected in this reissue application arose without any deceptive intent.

8. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

March 8, 2000
Date

Norval B. Galloway
Norval B. Galloway, Reg. No. 33,595
Patent Counsel
Vysis, Inc.
3100 Woodcreek Drive
Downers Grove, Illinois 60515

LAW OFFICES
INNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
ASHINGTON, DC 20005
202-408-4000

** TOTAL PAGE.04 **

-- LETTERS PATENT --
-- Attorney Docket No. 25,835.11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentees:	M. L. Collins, et al.
U.S. Patent No.	5,750,338
Issue Date:	May 12, 1998
Title:	TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS
Art Unit:	1807

Revocation of Power Of Attorney
Appointment of Attorneys

Commissioner for Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Vysis, Inc., assignee of the above-captioned letters patent and a corporation of the state of Delaware, through its duly delegated representative, hereby revokes all prior powers of attorney submitted previously in this patent.

Further, Vysis, Inc. through its duly delegated representative, hereby appoints William. E. Murray, Registration No. 30,303, and Norval B. Galloway, Registration No. 33,595 as its principal attorneys to have full power to transact all business in the Patent and Trademark Office connected with respect to the issued patent and to prosecute any underlying or related continuation, divisional, reissue and reexamination application thereof, including the power to revoke the power of attorney of any associate attorney hereto.

Charles E. Lipsey, Registration No. 28,165; Charles E. Van Horn, Registration No. 40,266; and Thomas W. Banks, Registration No. 32,719 are hereby appointed associate attorneys in the above-captioned patent with full power to transact all business in the Patent and Trademark Office with respect to the issued patent and to prosecute any underlying or related continuation, divisional, reissue and reexamination application thereof.

Please direct all future communications regarding the above-captioned patent to Norval B. Galloway c/o VYSIS, INC. at the address listed below.

Respectfully submitted,

Date: 12/8/98

By: Norval B Galloway

VYSIS, INC.
3100 Woodcreek Drive
Downers Grove, Illinois 60515-5400

Norval B. Galloway
Patent Counsel For Vysis, Inc.
Registration No. 33,595
Phone: (630) 271-7417
Facsimile: (630) 271-7054

PATENT
Attorney Docket No. 1147-0142

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Reissue Application of: U.S. Patent No. 5,750,338	)	
Mark L. Collins et al.	)	Group Art Unit: Unassigned
Reissue Serial No.: Unassigned	)	Examiner: Unassigned
Reissue Application Filed: Herewith	)	
For: TARGET AND BACKGROUND CAPTURE METHODS WITH AMPLIFICATION FOR AFFINITY ASSAYS	)	

BOX REISSUE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

ASSOCIATE POWER OF ATTORNEY

I hereby appoint Jean B. Fordis, Reg. No. 32,984, as an associate attorney to prosecute this reissue application and to transact all business in the Patent and Trademark Office connected therewith.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005
202-408-4000

Please send all future correspondence and Office Actions to the following address:

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.
1300 I Street, N.W.
Washington, D.C. 20005-3315
(202) 408-4000

Respectfully submitted,

March 8, 2000
Date

Norval B. Galloway, Reg. No. 33,595
Patent Counsel
Vysis, Inc.
3100 Woodcreek Drive
Downers Grove, Illinois 60515

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000